<PAGE>
<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
-----------------------
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED OCTOBER 31, 1998 COMMISSION FILE NO. 1-8597
-----------------------
THE COOPER COMPANIES, INC.
(Exact name of registrant as specified in its charter)
-----------------------
<TABLE>
<S> <C>
Delaware 94-2657368
(State or other jurisdiction (I.R.S. Employer
of incorporation) Identification No.)
6140 Stoneridge Mall Road, Suite 590 94588
Pleasanton, California (Zip Code)
(Address of principal executive offices)
</TABLE>
925-460-3600
(Registrant's telephone number, including area code)
-----------------------
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:
<TABLE>
<CAPTION>
Name of each exchange
Title of each class on which registered
------------------- -------------------
<S> <C>
Common Stock, $.10 Par Value, and New York Stock Exchange
associated Rights Pacific Exchange
</TABLE>
SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:
None
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months, and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [X]
Aggregate market value of the voting stock held by non-affiliates of the
registrant as of December 31, 1998: Common Stock, $.10 Par Value --
$297,773,840.
Number of shares outstanding of the registrant's common stock, as of
December 31, 1998: 14,913,957.
DOCUMENTS INCORPORATED BY REFERENCE:
<TABLE>
<CAPTION>
Document Part of Form 10-K
-------- -----------------
<S> <C>
Portions of the Annual Report to Stockholders for the Parts I and II
fiscal year ended October 31, 1998
Portions of the Proxy Statement for the Annual Part III
Meeting of Stockholders to be held March 18, 1999
</TABLE>
<PAGE>
<PAGE>
PART I
ITEM 1. BUSINESS.
INTRODUCTION
The Cooper Companies, Inc. ("Cooper" or the "Company"), through its
major subsidiaries, develops, manufactures and markets healthcare products,
including hard and soft daily, flexible and extended wear contact lenses, and
diagnostic products and surgical instruments and related products. In October
1998, the Company's Management and Board of Directors declared its Hospital
Group of America, Inc. ("HGA") business a discontinued operation.
FORWARD-LOOKING STATEMENTS
Statements in this report that are not based on historical fact may be
"forward-looking statements" as defined by the Private Securities Litigation
Reform Act of 1995. They include words like "may," "will," "expect," "estimate,"
"anticipate," "continue" or similar terms and reflect Cooper's current analysis
of existing trends. Actual results could differ materially from those indicated
due to: major changes in business conditions and the economy, loss of key senior
management, major disruptions in the operations of Cooper's manufacturing
facilities, new competitors or technologies, significant disruptions caused by
the failure of third parties to address the Year 2000 issue or by unforeseen
delays in completing Cooper's Year 2000 compliance program, acquisition
integration costs, foreign currency exchange exposure including the potential
impact of the Euro, investments in research and development and other start-up
projects, dilution to earnings per share from acquisitions or issuing stock,
regulatory issues, significant environmental clean-up costs above those already
accrued, litigation costs, costs of business divestitures, in the Company's SEC
reports, including this section entitled "Business" in this Form 10-K and the
related portions of the Company's 1998 Annual Report to Stockholders (the "1998
Annual Report") incorporated by reference herein, which 1998 Annual Report is
included as Exhibit 13 to this Form 10-K.
GENERAL DESCRIPTION AND DEVELOPMENT OF BUSINESSES
The information required for this item is contained under the caption
"Letter to Shareholders" in the 1998 Annual Report, which information is
incorporated herein by reference.
RESEARCH AND DEVELOPMENT
Company-sponsored research and development expenditures during the
fiscal year ended October 31, were $1.9 million in 1998, $1.7 million in 1997
and $1.2 million in 1996. During fiscal 1998, CooperVision spent about 49% and
CooperSurgical spent about 51% of the total. Cooper did not conduct any
customer-sponsored research and development programs.
Cooper employs 21 people in its research and development and
manufacturing engineering departments. Outside specialists in lens design
formulation science, polymer chemistry, microbiology and biochemistry support
product development and clinical research for CooperVision products.
CooperSurgical conducts research and development in-house and also employs
outside surgical specialists, including members of its surgical advisory board.
1
<PAGE>
<PAGE>
GOVERNMENT REGULATION
The U.S. Food and Drug Administration ("FDA"), other federal agencies
and foreign ministries of health regulate the development, testing, production
and marketing of the Company's products. The Federal Food, Drug and Cosmetic Act
and other statutes and regulations govern the testing, manufacturing, labeling,
storage, advertising and promotion of such products. If applicable regulations
are not followed, companies are subject to fines, product recall or seizure,
suspension of production and criminal prosecution.
Cooper develops and markets medical devices under different levels of
FDA regulation depending upon the classification of the device. Class III
devices, such as flexible and extended wear contact lenses, require extensive
premarket testing and approval, while Class I and II devices require
substantially lower levels of regulation.
Before a new contact lens can be sold commercially, CooperVision ("CVI")
must complete these steps: (1) compile data on its chemistry and toxicology, (2)
determine its microbiological profile and (3) define the proposed manufacturing
process. This data must be submitted to the FDA to support an application for an
Investigational Device Exemption. Once this is granted, clinical trials can
begin. These are subject to review and approval by an Institutional Review Board
and, where a lens is determined to have a significant risk, the FDA. After the
clinical trials are completed, a Premarket Approval Application must be
submitted and approved by the FDA.
In connection with some of its new surgical products, CooperSurgical
("CSI") can submit an expedited procedure known as a 510(k) application for
premarket notification to the FDA. Any product that can demonstrate that it is
substantially equivalent to another device marketed before May 28, 1976 can use
this procedure. If the new product is not substantially equivalent to a
preexisting device or if the FDA rejected a claim of substantial equivalence,
FDA approval to market would require extensive preclinical and clinical testing.
This would increase the cost and would delay product marketing substantially.
FDA and state regulations also require the Company to adhere to
applicable "good manufacturing practices" ("GMP"). They require detailed quality
assurance and record keeping and periodic unscheduled regulatory inspections.
The Company believes it is in substantial compliance with GMP regulations.
Health authorities in foreign countries regulate Cooper's human device
clinical trials and medical device sales. The regulations vary widely from
country to country. Even if the FDA has approved a product, the regulatory
agencies in each country must approve new products before they are marketed.
These regulatory procedures require considerable resources and usually
result in a substantial time lag between new product development and marketing.
Cooper cannot assure that all necessary approvals will be obtained, or obtained
in a timely manner. If the Company does not maintain compliance with regulatory
standards or if problems occur after marketing, product approval may be
withdrawn.
ISO 9000 CERTIFICATION AND CE MARK APPROVAL
In addition to the FDA regulatory requirements, the Company also
maintains ISO 9000 certification and CE Mark approvals for all lens products.
These quality programs and approvals are required by the European Medical Device
Directive and must be maintained for all products intended to be sold in the
European market. In order to maintain these prestigious quality benchmarks, the
Company is subjected to rigorous biannual reassessment audits of their quality
systems and procedures by globally recognized notified bodies and agencies.
2
<PAGE>
<PAGE>
RAW MATERIALS
In general, CVI's raw materials consist of various polymers and
packaging materials. There are alternative supply sources of all of these
materials. Raw materials used by CSI or its suppliers are generally available
from more than one source. However, because some products require specialized
manufacturing procedures, CSI could experience inventory shortages if it needed
an alternative manufacturer on short notice.
MARKETING AND DISTRIBUTION
In the United States, Canada and certain European countries, CVI markets
its products through its field sales representatives, who call on
ophthalmologists, optometrists, opticians and optical chains. In the United
States, field sales representatives also call on distributors. In certain other
European counties, CVI uses distributors and has given them the exclusive right
to market our products.
CSI's products are marketed worldwide by a network of field sales
representatives and distributors. In the United States, CSI also uses
telemarketing, direct mail, advertising in professional journals and a direct
mail catalog.
PATENTS, TRADEMARKS AND LICENSING AGREEMENTS
Cooper owns or licenses a variety of domestic and foreign patents which,
in total, are material to its businesses. The names of certain of Cooper's
products are protected by trademark registrations in the United States Patent
and Trademark Office and, in some cases, also in foreign trademark offices.
Applications are pending for additional trademark registrations. These
trademarks are valuable as they contribute to the brand identity of Cooper's
products. Cooper aggressively enforces and defends its patents and other
proprietary technology.
DEPENDENCE ON CUSTOMERS
Cooper's business does not materially depend on any one customer or any
one affiliated group of customers.
GOVERNMENT CONTRACTS
Cooper's business is not materially subject to profit renegotiation or
termination of contracts or subcontracts at the election of the United States
government.
COMPETITION
Each of Cooper's businesses operates in a highly competitive
environment. Competition in the healthcare industry revolves around the search
for technological and therapeutic innovations in the prevention, diagnosis and
treatment of illness or disease. Cooper competes primarily on the basis of
product quality, program differentiation, technological benefit, service and
reliability.
Many companies develop and manufacture contact lenses. CVI competes
primarily on its product quality, service and reputation among medical
professionals and by participating in specialty niche markets.
3
<PAGE>
<PAGE>
It sponsors clinical studies to generate medical information to improve its
lenses. Major competitors have greater financial resources and larger research
and development and sales forces than CVI. Many of these competitors offer a
greater range of contact lenses and a variety of other eyecare products,
including lens care products and ophthalmic pharmaceuticals, which may give them
a competitive advantage in marketing their lenses to high volume contract
accounts.
In the surgical segment, competitive factors include technological and
scientific advances, product quality, price and effective communication of
product information to physicians and hospitals. CSI believes that it benefits,
in part, from the technological advantages of certain of its products and from
developing new medical procedures that can create new markets for equipment and
instruments. CSI competes by focusing on distinct niche markets and by supplying
these with high quality equipment, instruments and disposable products. For
certain procedures, medical practitioners can obtain all of the equipment,
instruments and disposable products from CSI. As CSI develops products for new
medical procedures, it offers to train medical professionals to perform them.
CSI competes with a number of manufacturers in each of its niche markets,
including larger manufacturers with greater financial and personnel resources
who sell a substantially larger number of product lines.
BACKLOG
Backlog is not a material factor in Cooper's businesses.
SEASONALITY
CVI's contact lens sales in the first fiscal quarter are generally lower
than subsequent quarters as fewer patients visit practitioners during the
holiday season.
COMPLIANCE WITH ENVIRONMENTAL LAWS
Federal, state and local provisions that regulate the discharge of
materials into the environment, or relate to the protecting of the environment,
do not currently materially effect Cooper's capital expenditures, earnings or
competitive position. See "Environmental" in Note 11 of Notes to Consolidated
Financial Statements of the Company included in the 1998 Annual Report,
regarding certain anticipated remediation costs, which information is
incorporated herein by reference.
WORKING CAPITAL
Cooper's businesses have not required any material working capital
arrangements in the past five years.
FINANCIAL INFORMATION ABOUT BUSINESS SEGMENTS, GEOGRAPHIC AREAS, FOREIGN
OPERATIONS AND EXPORT SALES
The information required for this item is included in Note 12 "Business
Segment Information" of Notes to Consolidated Financial Statements of the
Company included in the 1998 Annual Report, which information is incorporated
herein by reference.
4
<PAGE>
<PAGE>
EMPLOYEES
On October 31, 1998, Cooper and its continuing operations employed
approximately 1,900 persons. The Company believes that its relations with its
employees are good.
ITEM 2. PROPERTIES.
The following are the principal facilities of Cooper's continuing
operations as of October 31, 1998:
<TABLE>
<CAPTION>
APPROXIMATE OWNED
FLOOR AREA OR LEASE
LOCATION OPERATIONS (SQ. FT.) LEASED EXPIRATION
-------- ---------- --------- ------ ----------
<S> <C> <C> <C> <C>
United States
Pleasanton, CA Executive Offices 13,700 Leased Sept. 2000
Irvine, CA Executive Offices, CVI
Offices, Distribution
and Customer Service 15,400 Leased Jan. 2000
Huntington Beach, CA CVI Manufacturing &
Technical Offices 16,500 Leased March 2002
Fairport, NY CVI Administrative
Offices & Marketing 20,100 Leased April 2002
Scottsville, NY CVI Manufacturing,
Distribution and
Warehouse Facilities 49,500 Owned N/A
Shelton, CT CSI Manufacturing,
Research and
Development, Marketing,
Distribution and
Warehouse Facilities 35,000 Leased Dec. 2002
Canada
Markham, Ont. CVI Offices,
Manufacturing
Distribution and
Warehouse Facilities 21,000 Leased Feb. 2000
United Kingdom
Hamble, Hampshire, Aspect Manufacturing,
England Research and Development,
Marketing and Admin.
Offices 93,800 Owned N/A
Fareham, Hampshire, Distribution and Customer
England Service 30,800 Leased Jan. 2018
Fareham, Hampshire, Manufacturing and
England Warehouse 27,100 Leased June 2018
</TABLE>
The Company believes its properties are suitable and adequate for its
businesses.
5
<PAGE>
<PAGE>
ITEM 3. LEGAL PROCEEDINGS.
The information required for this item is contained under the caption
"Pending Litigation - GT Labs" in Note 11 of Notes to Consolidated Financial
Statements of the Company included in the 1998 Annual Report, which information
is incorporated herein by reference.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
During the fourth quarter of fiscal 1998, the Company did not submit any
matters to a vote of the Company's security holders.
6
<PAGE>
<PAGE>
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.
The information required for this item is contained under the caption
"Common Stock Price Range" in the 1998 Annual Report, which information is
incorporated herein by reference.
ITEM 6. SELECTED FINANCIAL DATA.
The information required for this item is contained under the caption
"Five Year Financial Highlights" in the 1998 Annual Report, which information is
incorporated herein by reference.
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS.
The information required for this item is contained under the caption
"Management's Discussion and Analysis of Financial Condition and Results of
Operations" in the 1998 Annual Report, which information is incorporated herein
by reference.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK
The Company is primarily exposed to market risks that relate to changes
in interest rates, foreign currency fluctuations and in the market value of its
long-term debt obligations. The Company seeks to minimize its exposure to the
impact of changing interest rates and foreign currency fluctuations by entering
into interest rate swaps and foreign currency forward exchange contracts. The
Company generally does not enter into derivative financial instrument
transactions for speculative purposes. Additional information for this item is
contained under the caption "Derivatives" in Note 1 "Summary of Significant
Accounting Policies" and in Note 7 "Financial Instruments" in the 1998 Annual
Report, which information is incorporated herein by reference.
LONG-TERM DEBT
The following table sets forth as of October 31, 1998, the Company's
long-term debt obligations, principal cash flows by scheduled maturity, weighted
average interest rates and estimated fair market value.
<TABLE>
<CAPTION>
Expected Maturity Date - Fiscal Year
------------------------------------------------------------------------------------
There- Fair
1999 2000 2001 2002 2003 after Total Value
---- ---- ---- ---- ---- ----- ----- -----
<S> <C> <C> <C> <C> <C> <C> <C> <C>
($ in Millions)
Long-term Debt
Fixed interest rate($US) $ 4.0 $ - $ - $ - $ 23.6 $ - $ 27.6 $ 27.6
Average interest rate 8.00% 8.00% 8.00% 8.00% 8.00% -
Variable interest rate ($US) $ 0.2 $ 0.2 $ 0.3 $ 22.1 $ 17.7 $ 1.6 $ 42.1 $ 42.1
Average interest rate 6.40% 6.51% 6.64% 6.74% 5.25% 4.99%
</TABLE>
7
<PAGE>
<PAGE>
INTEREST RATE EXPOSURES
The Company enters into interest rate swap agreements to reduce the
impact of changes in interest rates on its variable rate long-term debt
obligations. The Company currently has two interest rate swap agreements on a
total of $20.5 million of its outstanding variable rate debt obligations. These
instruments have the effect of converting variable rate instruments to fixed
rate instruments. The interest rate swap agreements assure that the Company will
pay 6.19% and 4.88% on the aforementioned $20.5 million long-term debt
obligations for the periods ending November 2002 (principal amount $17.5
million) and January 2012 (principal amount $3 million), respectively. The table
below sets forth the notional amount and weighted average interest rates of each
of the Company's interest rate swaps by maturity. The receive rate is based on
October 31, 1998 rates, and projected based on the consumer price index.
Notional amounts are used to calculate the contractual payments to be made under
the contracts.
<TABLE>
<CAPTION>
Notional Amounts Maturing in Fiscal Year
------------------------------------------------------------------------------------
There- Fair
1999 2000 2001 2002 2003 after Total Value
---- ---- ---- ---- ---- ----- ----- -----
<S> <C> <C> <C> <C> <C> <C> <C> <C>
($ in Millions)
Interest rate swaps
Variable to fixed ($US) $ - $ - $ - $ 17.5 $ - $ - $ 17.5 $ 18.2
Average pay rate 6.19% 6.19% 6.19% 6.19% - - 6.19%
Average receive rate 5.93% 6.03% 6.14% 6.24% - - 6.03%
Variable to fixed ($US) $ 0.2 $ 0.2 $ 0.3 $ 0.3 $ 0.3 $ 1.7 $ 3.0 $ 3.2
Average pay rate 4.88% 4.88% 4.88% 4.88% 4.88% 4.88% 4.88%
Average receive rate 4.27% 4.34% 4.42% 4.49% 4.57% 4.99% 4.75%
</TABLE>
FOREIGN CURRENCY EXPOSURES
The Company uses forward exchange contracts to minimize the effect of
foreign currency fluctuations on its long-term debt obligations denominated in
Great Britain Pounds ("GBP"), which debt was incurred to fund a portion of the
Company's acquisition of Aspect Vision Care Ltd. (see caption "Aspect
Acquisition" in Note 2 "Acquisitions" in the 1998 Annual Report, which
information is incorporated herein by reference). The following table provides
information on the Company's foreign currency forward exchange contracts. The
information is provided in U.S. Dollar equivalent amounts, as presented in the
Company's financial statements. The table presents the notional amounts at the
contract exchange rates and the weighted average contractual foreign currency
exchange rates by expected maturity dates.
<TABLE>
<CAPTION>
Notional Amounts Maturing in Fiscal Year
------------------------------------------------------------------------------------
There- Fair
1999 2000 2001 2002 2003 after Total Value
---- ---- ---- ---- ---- ----- ----- -----
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Foreign Contracts to Buy G.B.P.:
Notional amount (in millions) $ 3.5 $ 1.8 $ 8.5 $ 3.5 $ 27.3 $ - $ 44.6 $ 43.8
Average contractual exchange rate $ 1.62 $ 1.61 $ 1.63 $ 1.62 $ 1.62 - $ 1.62
</TABLE>
8
<PAGE>
<PAGE>
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
The information required for this item is included under the captions
"Consolidated Balance Sheets," "Consolidated Statements of Income,"
"Consolidated Statements of Cash Flows," "Notes to Consolidated Financial
Statements," "Independent Auditors' Report" and "Two Year Quarterly Financial
Data" in the 1998 Annual Report, which information is incorporated herein by
reference.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE.
Not applicable.
9
<PAGE>
<PAGE>
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT.
The information contained under the heading "Election of Directors" and
"Executive Officers of the Company" in the Company's Proxy Statement for the
Annual Meeting of Stockholders scheduled to be held on March 18, 1999 (the "1999
Proxy Statement") is incorporated herein by reference with respect to each of
the Company's directors and the executive officers who are not also directors of
the Company.
ITEM 11. EXECUTIVE COMPENSATION.
The information contained under the subheadings "Executive Compensation"
and "Compensation of Directors" of the "Election of Directors" section of the
1999 Proxy Statement is incorporated herein by reference with respect to the
Company's chief executive officer, the four other most highly compensated
executive officers of the Company and the Company's directors.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.
The information contained under the subheadings "Securities Held by
Management" and "Principal Security Holders" of the "Election of Directors"
section of the 1999 Proxy Statement is incorporated herein by reference with
respect to certain beneficial owners, the directors and management.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.
The information required for this item is contained in the heading
"Aspect Acquisition" in Note 2 "Acquisitions" in the 1998 Annual Report, which
information is incorporated herein by reference.
10
<PAGE>
<PAGE>
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K.
(a) Documents filed as part of this report:
1. Description of the Business.
The general description of the business and its general
development are contained under the caption "Letter to Shareholders"
in the 1998 Annual Report, which information is incorporated herein
by reference.
2. Accountants' Consent and Report on Schedule.
3. Financial Statement Schedule of the Company.
<TABLE>
<CAPTION>
SCHEDULE
NUMBER DESCRIPTION
-------- -----------
<S> <C>
Schedule II Valuation and Qualifying Accounts
</TABLE>
All other schedules for which provision is made in the
applicable accounting regulations of the Securities and Exchange
Commission are not required under the related instructions or are not
applicable and, therefore, have been omitted.
11
<PAGE>
<PAGE>
ACCOUNTANTS' CONSENT AND REPORT ON SCHEDULE
The Board of Directors
THE COOPER COMPANIES, INC.
The audits of the consolidated financial statements of The Cooper
Companies, Inc. and subsidiaries referred to in our report dated December 10,
1998, which is incorporated herein by reference, included the related financial
statement schedule for each of the years in the three-year period ended October
31, 1998 as listed in Item 14 of the Annual Report on Form 10-K. This financial
statement schedule is the responsibility of the Company's management. Our
responsibility is to express an opinion on this financial statement schedule
based on our audits. In our opinion, such financial statement schedule, when
considered in relation to the basic consolidated financial statements taken as a
whole, presents fairly in all material respects the information set forth
therein.
We consent to incorporation by reference in the Registration Statement
Nos. 33-50016, 33-11298, 333-22417, 333-25051 and 333-27639 on Form S-3 and
Registration Statement Nos. 333-10997, 33-27938, 33-36325, 33-36326 and
333-58839 on Form S-8 of The Cooper Companies, Inc. of our reports dated
December 10, 1998, relating to the consolidated balance sheets of The Cooper
Companies, Inc. and subsidiaries as of October 31, 1998 and 1997 and the related
consolidated statements of income and cash flows for each of the years in the
three-year period ended October 31, 1998, and related schedule, which reports
appear in or are incorporated by reference in the October 31, 1998 Annual Report
on Form 10-K of The Cooper Companies, Inc.
KPMG LLP
San Francisco, California
January 25, 1999
12
<PAGE>
<PAGE>
SCHEDULE II
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
VALUATION AND QUALIFYING ACCOUNTS
THREE YEARS ENDED OCTOBER 31, 1998
<TABLE>
<CAPTION>
ADDITIONS
BALANCE AT CHARGED TO DEDUCTIONS/ BALANCE
BEGINNING COSTS AND RECOVERIES/ AT END
OF YEAR EXPENSES OTHER(1) OF YEAR
------- -------- -------- -------
(IN THOUSANDS)
<S> <C> <C> <C> <C>
Allowance for doubtful accounts:
Year ended October 31, 1998...........$ 721 $ 283 $ 83 $ 1,087
======== ======== ======== ========
Year ended October 31, 1997...........$ 716 $ 155 $ (150) $ 721
======== ======== ======== ========
Year ended October 31, 1996...........$ 548 $ 11 $ 157 $ 716
======== ======== ======== ========
</TABLE>
- ---------
All prior periods have been restated to exclude Hospital Group of America as it
was declared a discontinued operation.
(1) Principally uncollectible accounts written off, net of accounts
recovered that were previously written off.
13
<PAGE>
<PAGE>
3. EXHIBITS.
<TABLE>
<CAPTION>
EXHIBIT
NUMBER PAGE
- ------- ----
<S> <C> <C>
3.1 - Restated Certificate of Incorporation, as partially amended, incorporated by
reference to Exhibit 4(a) to the Company's Registration Statement on Form S-3
(No. 33-17330) and Exhibits 19(a) and 19(c) to the Company's Quarterly Report on
Form 10-Q for the Fiscal Quarter ended April 30, 1988............................
3.2 - Certificate of Amendment of Restated Certificate of Incorporation dated
September 21, 1995 incorporated by reference to Exhibit 3.2 to the Company's
Annual Report on Form 10-K for the fiscal year ended October 31, 1995............
3.3 - Amended and Restated By-Laws, incorporated by reference to Exhibit 3.2 to the
Company's Report on Form 8-A dated January 18, 1994..............................
4.1 - Certificate of Elimination of Series A Junior Participating Preferred Stock of
The Cooper Companies, Inc. filed with the Delaware Secretary of State on October
30, 1997, incorporated by reference to Exhibit 4.1 on Form 10-K for fiscal year
ended October 31, 1997...........................................................
4.2 - Rights Agreement, dated as of October 29, 1997, between the Company and American
Stock Transfer & Trust Company, incorporated by reference to Exhibit 4.0 to the
Company's Current Report on Form 8-K dated October 29, 1997......................
4.3 - Amendment No. 1 to Rights Agreement dated September 25, 1998, incorporated by
reference to Exhibit 99.1 of the Company's Current Report on Form 8-K dated
September 25, 1998...............................................................
4.4 - Certificate of Designations of Series A Junior Participating Preferred Stock of
The Cooper Companies, Inc., incorporated by reference to Exhibit 4.0 of the
Company's Current Report on Form 8-K dated October 29, 1997......................
10.1 - 1998 Long-Term Incentive Plan, incorporated by reference to Exhibit A of the
Company's Proxy Statement for its 1998 Annual Meeting of Shareholders held on
April 2, 1998....................................................................
10.2 - Amendment No. 1 to 1998 Long-Term Incentive Plan of The Cooper Companies, Inc.
dated April 2, 1998, incorporated by reference to Exhibit 4.7 to the Company's
post-effective Amendment No. 1 to Form S-8 Registration Statement filed on
January 20, 1999.................................................................
10.3 - Severance Agreement entered into as of June 10, 1991, by and between
CooperVision, Inc. and A. Thomas Bender, incorporated by reference to Exhibit
10.26 to Amendment No. 1 to the Company's Annual Report on Form 10-K for the
fiscal year ended October 31, 1992...............................................
10.4 - Letter dated March 25, 1994, to A. Thomas Bender from the Chairman of the
Compensation Committee of the Company's Board of Directors, incorporated by
reference to Exhibit 10.4 to the Company's Annual Report on Form 10-K for the
fiscal year ended October 31, 1994...............................................
10.5 - Severance Agreement entered into as of April 26, 1990, by and between Nicholas
J. Pichotta and the Company incorporated by reference to Exhibit 10.8 to the
Company's Annual Report on Form 10-K for fiscal year ended October 31, 1995......
10.6 - Letter Agreement dated November 1, 1992, by and between Nicholas J. Pichotta and
the Company incorporated by reference to Exhibit 10.9 to the Company's Annual
Report on Form 10-K for the fiscal year ended October 31, 1995...................
10.7 - Severance Agreement entered into as of August 21, 1989, by and between Robert S.
Weiss and the Company, incorporated by reference to Exhibit 10.28 to Amendment
No. 1 to the Company's Annual Report on Form 10-K for the fiscal year ended
October 31, 1992.................................................................
10.8 - 1996 Long-Term Incentive Plan for Non-Employee Directors of The Cooper
Companies, Inc., incorporated by reference to the Company's Proxy Statement for
its 1996 Annual Meeting of Stockholders..........................................
10.9 - Amendment No. 1 to 1996 Long-Term Incentive Plan for Non-Employee Directors of
The Cooper Companies, Inc., dated October 10, 1996, incorporated by reference to
Exhibit 10.14 to the Company's Annual Report on Form 10-K for the fiscal year
ended October 31, 1996...........................................................
</TABLE>
14
<PAGE>
<PAGE>
<TABLE>
<CAPTION>
EXHIBIT
NUMBER PAGE
- ------- ----
<S> <C> <C>
10.10 - Amendment No. 2 to 1996 Long-Term Incentive Plan for Non-Employee Directors of
The Cooper Companies, Inc., dated October 29, 1997, incorporated by reference
to Exhibit 10.15 to the Company's Annual Report on Form 10-K for the fiscal
year ended October 31, 1997.......................................................
10.11 - Agreement dated as of September 28, 1993, among Medical Engineering Corporation,
Bristol-Myers Squibb Company and the Company, incorporated by reference to
Exhibit 10.1 to the Company's Current Report on Form 8-K dated October 1, 1993....
11* - Calculation of Earnings per share................................................
13 - 1998 Annual Report to Stockholders. The following portions of such report are
incorporated by reference in this document and are deemed "filed." Letter to
Shareholders and Financial Section which includes: Five Year Financial
Highlights, Two Year Quarterly Information, Quarterly Common Stock Price Range,
Management's Discussion and Analysis of Financial Condition and Results of
Operations, the Consolidated Financial Statements and the Notes thereto, and the
Independent Auditors' Report.....................................................
21 - Subsidiaries.....................................................................
27 - Financial Data Schedule, incorporated by reference to Exhibit 27 on the
Company's Current Report on Form 8-K dated December 14, 1998.....................
</TABLE>
* The information called for in this exhibit is contained in Note 4, "Earnings
Per Share," in the 1998 Annual Report, which information is incorporated
herein by reference.
(b) REPORTS ON FORM 8-K.
August 26, 1998 -- Item 5. Other Events.
September 03, 1998 -- Item 5. Other Events.
September 25, 1998 -- Item 5. Other Events.
October 02, 1998 -- Item 5. Other Events.
October 21, 1998 - Item 5. Other Events.
October 26, 1998 -- Item 5. Other Events.
15
<PAGE>
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized, on January 27, 1999.
THE COOPER COMPANIES, INC.
By: /s/ A. THOMAS BENDER
--------------------------------
A. THOMAS BENDER
PRESIDENT, CHIEF EXECUTIVE
OFFICER AND DIRECTOR
Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the
registrant and in the capacities indicated on the dates set forth opposite their
respective names.
<TABLE>
<CAPTION>
SIGNATURE CAPACITY DATE
--------- -------- ----
<S> <C> <C>
/s/ ALLAN E. RUBENSTEIN Chairman of the Board of Directors January 27, 1999
- ---------------------------------
(ALLAN E. RUBENSTEIN)
/s/ A. THOMAS BENDER President, Chief Executive Officer January 27, 1999
- --------------------------------- and Director
(A. THOMAS BENDER)
/s/ ROBERT S. WEISS Executive Vice President, Treasurer, January 27, 1999
- --------------------------------- Chief Financial Officer and Director
(ROBERT S. WEISS)
/s/ STEPHEN C. WHITEFORD Vice President and Corporate January 27, 1999
- --------------------------------- Controller
(STEPHEN C. WHITEFORD)
/s/ MICHAEL H. KALKSTEIN Director January 27, 1999
- ---------------------------------
(MICHAEL H. KALKSTEIN)
/s/ MOSES MARX Director January 27, 1999
- ---------------------------------
(MOSES MARX)
/s/ DONALD PRESS Director January 27, 1999
- ---------------------------------
(DONALD PRESS)
/s/ STEVEN ROSENBERG Director January 27, 1999
- ---------------------------------
(STEVEN ROSENBERG)
/s/ STANLEY ZINBERG Director January 27, 1999
- ---------------------------------
(STANLEY ZINBERG)
</TABLE>
16
<PAGE>
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
LOCATION OF
EXHIBIT IN
EXHIBIT SEQUENTIAL
NUMBER DESCRIPTION OF DOCUMENT NUMBER SYSTEM
- ------- ----------------------- -------------
<S> <C> <C>
3.1 - Restated Certificate of Incorporation, as partially amended, incorporated by
reference to Exhibit 4(a) to the Company's Registration Statement on Form S-3
(No. 33-17330) and Exhibits 19(a) and 19(c) to the Company's Quarterly Report
on Form 10-Q for the Fiscal Quarter ended April 30, 1988........................
3.2 - Certificate of Amendment of Restated Certificate of Incorporation dated
September 21, 1995 incorporated by reference to Exhibit 3.2 to the Company's
Annual Report on Form 10-K for the fiscal year ended October 31, 1995...........
3.3 - Amended and Restated By-Laws, incorporated by reference to Exhibit 3.2 to the
Company's Report on Form 8-A dated January 18, 1994.............................
4.1 - Certificate of Elimination of Series A Junior Participating Preferred Stock of
The Cooper Companies, Inc. filed with the Delaware Secretary of State on
October 30, 1997, incorporated by reference to Exhibit 4.1 on Form 10-K for
fiscal year ended October 31, 1997..............................................
4.2 - Rights Agreement, dated as of October 29, 1997, between the Company and
American Stock Transfer & Trust Company, incorporated by reference to Exhibit
4.0 to the Company's Current Report on Form 8-K dated October 29, 1997..........
4.3 Amendment No. 1 to Rights Agreement dated September 26, 1998, incorporated by
reference to Exhibit 99.1 of the Company's Current Report on Form 8-K dated
September 25, 1998..............................................................
4.4 - Certificate of Designations of Series A Junior Participating Preferred Stock
of The Cooper Companies, Inc., incorporated by reference to Exhibit 4.0 of the
Company's Current Report on Form 8-K dated October 29, 1997.....................
10.1 - 1998 Long-Term Incentive Plan, incorporated by reference to Exhibit A of the
Company's Proxy Statement for its 1998 Annual Meeting of Shareholders held on
April 2, 1998...................................................................
10.2 - Amendment No. 1 to 1998 Long-Term Incentive Plan of The Cooper Companies, Inc.
dated April 2, 1998, incorporated by reference to Exhibit 4.7 to the Company's
post-effective Amendment No. 1 to Form S-8 Registration Statement filed on
January 20, 1999................................................................
10.3 - Severance Agreement entered into as of June 10, 1991, by and between
CooperVision, Inc. and A. Thomas Bender, incorporated by reference to Exhibit
10.26 to Amendment No. 1 to the Company's Annual Report on Form 10-K for the
fiscal year ended October 31, 1992..............................................
10.4 - Letter dated March 25, 1994, to A. Thomas Bender from the Chairman of the
Compensation Committee of the Company's Board of Directors, incorporated by
reference to Exhibit 10.4 to the Company's Annual Report on Form 10-K for the
fiscal year ended October 31, 1994..............................................
10.5 - Severance Agreement entered into as of April 26, 1990, by and between Nicholas
J. Pichotta and the Company incorporated by reference to Exhibit 10.8 to the
Company's Annual Report on Form 10-K for fiscal year ended October 31, 1995.....
10.6 - Letter Agreement dated November 1, 1992, by and between Nicholas J. Pichotta
and the Company incorporated by reference to Exhibit 10.9 to the Company's
Annual Report on Form 10-K for the fiscal year ended October 31, 1995...........
10.7 - Severance Agreement entered into as of August 21, 1989, by and between Robert
S. Weiss and the Company, incorporated by reference to Exhibit 10.28 to
Amendment No. 1 to the Company's Annual Report on Form 10-K for the fiscal
year ended October 31, 1992.....................................................
</TABLE>
17
<PAGE>
<PAGE>
<TABLE>
<CAPTION>
LOCATION OF
EXHIBIT IN
EXHIBIT SEQUENTIAL
NUMBER DESCRIPTION OF DOCUMENT NUMBER SYSTEM
- ------- ----------------------- -------------
<S> <C> <C>
10.8 - 1996 Long-Term Incentive Plan for Non-Employee Directors of The Cooper
Companies, Inc., incorporated by reference to the Company's Proxy Statement
for its 1996 Annual Meeting of Stockholders.....................................
10.9 - Amendment No. 1 to 1996 Long-Term Incentive Plan for Non-Employee Directors of
The Cooper Companies, Inc., dated October 10, 1996, incorporated by reference
to Exhibit 10.14 to the Company's Annual Report on Form 10-K for the fiscal
year ended October 31, 1996.....................................................
10.10 - Amendment No. 2 to 1996 Long-Term Incentive Plan for Non-Employee Directors of
The Cooper Companies, Inc., dated October 29, 1997, incorporated by reference
to Exhibit 10.15 to the Company's Annual Report on Form 10-K for the fiscal
year ended October 31, 1997.....................................................
10.11 - Agreement dated as of September 28, 1993, among Medical Engineering
Corporation, Bristol-Myers Squibb Company and the Company, incorporated by
reference to Exhibit 10.1 to the Company's Current Report on Form 8-K dated
October 1, 1993.................................................................
11* - Calculation of Earnings per share...............................................
13 - 1998 Annual Report to Stockholders. The following portions of such report are
incorporated by reference in this document and are deemed "filed." Letter to
Shareholders and Financial Section which includes: Five Year Financial
Highlights, Two Year Quarterly Information, Quarterly Common Stock Price
Range, Management's Discussion and Analysis of Financial Condition and Results
of Operations, the Consolidated Financial Statements and the Notes thereto,
and the Independent Auditors' Report............................................
21 - Subsidiaries....................................................................
27 - Financial Data Schedule, incorporated by reference to Exhibit 27 on the
Company's Current Report on Form 8-K dated December 14, 1998....................
</TABLE>
* The information called for in this exhibit is contained in Note 4, "Earnings
Per Share," in the 1998 Annual Report, which information is incorporated
herein by reference.
(b) REPORTS ON FORM 8-K.
August 26, 1998 -- Item 5. Other Events.
September 03, 1998 -- Item 5. Other Events.
September 25, 1998 -- Item 5. Other Events.
October 02, 1998 -- Item 5. Other Events.
October 21, 1998 -- Item 5. Other Events.
October 26, 1998 -- Item 5. Other Events.
18
STATEMENTS OF DIFFERENCES
The trademark symbol shall be expressed as..................... 'TM'
The registered symbol shall be expressed as.................... 'r'
The British pound sterling sign shall be expressed as.......... 'L'
<PAGE>
<PAGE>
1998 ANNUAL REPORT
NARROWING OUR FOCUS . EXPANDING OUR REACH
THE COOPER COMPANIES, INC.
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC.
IS A RAPIDLY GROWING SPECIALTY HEALTHCARE COMPANY. ITS BUSINESS UNITS
SERVE ATTRACTIVE NICHE MARKETS IN THE MEDICAL DEVICE MARKET WITH HIGH
QUALITY PRODUCTS AND SERVICES. COOPERVISION MARKETS A BROAD RANGE OF
CONTACT LENSES IN NORTH AMERICA AND EUROPE. COOPERSURGICAL MARKETS
DIAGNOSTIC PRODUCTS, SURGICAL INSTRUMENTS AND ACCESSORIES TO THE
WOMEN'S HEALTHCARE MARKET. IN OCTOBER 1998, HOSPITAL GROUP OF AMERICA,
COOPER'S PSYCHIATRIC SERVICES BUSINESS, WAS DECLARED A DISCONTINUED
OPERATION.
FORWARD-LOOKING STATEMENTS
Statements in this report that are not based on historical fact may be
"forward-looking statements" as defined by the Private Securities
Litigation Reform Act of 1995. They include words like "may," "will,"
"expect," "estimate," "anticipate," "continue" or similar terms and
reflect Cooper's current analysis of existing trends. Actual results
could differ materially from those indicated due to: major changes in
business conditions and the economy, loss of key senior Management,
major disruptions in the operations of Cooper's manufacturing
facilities, new competitors or technologies, significant disruptions
caused by the failure of third parties to address the Year 2000 issue
or by unforeseen delays in completing Cooper's Year 2000 compliance
program, acquisition integration costs, foreign currency exchange
exposure including the potential impact of the Euro, investments in
research and development and other start-up projects, dilution to
earnings per share from acquisitions or issuing stock, regulatory
issues, significant environmental clean-up costs above those already
accrued, litigation costs, costs of business divestitures, significant
delay or failure to complete the sale of Hospital Group of America
(HGA), and items listed in the Company's SEC reports, including its
Annual Report on Form 10-K for the year ended October 31, 1998.
CONTENTS
FISCAL 1998 FINANCIAL HIGHLIGHTS 2
LETTER TO SHAREHOLDERS 3
FINANCIAL SECTION 17
CORPORATE INFORMATION 54
<PAGE>
<PAGE>
FINANCIAL HIGHLIGHTS
Restated to reflect Hospital Group of America as a Discontinued Operation
<TABLE>
<CAPTION>
- -------------------------------------------------------------------------------------------------
Fiscal years ended October 31,
- -------------------------------------------------------------------------------------------------
(In mi1lions except per share data) 1998 % change 1997 % change
vs. 1997 vs. 1996
- -------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
REVENUE
CooperVision $ 119.2 86% $ 64.0 31%
CooperSurgical $ 28.0 13% $ 24.8 44%
Total $ 147.2 66% $ 88.8 34%
- -------------------------------------------------------------------------------------------------
OPERATING INCOME
CooperVisiion $ 34.6 50% $ 23.1 21%
CooperSurgical $ 2.1 (14%) $ 2.5 49%
Corporate Expenses $ (7.0) 21% $ (5.8) (11%)
Total $ 29.7 50% $ 19.8 39%
As a Percent of Revenue 20% -- 22% --
- -------------------------------------------------------------------------------------------------
EARNINGS
Net Income $ 39.8 27% $ 31.4 89%
As a Percent of Revenue 27% -- 35% --
From Continuing Operations $ 57.8 32% $ 43.7 180%
As a Percent of Revenue 39% -- 49% --
- -------------------------------------------------------------------------------------------------
DILUTED EARNINGS PER SHARE
Continuing Operations $ 3.79 14% $ 3.33 152%
Income Before Items Below: $ 1.51 17% $ 1.29 36%
Tax Benefit $ 2.28 12% $ 2.04 451%
Extraordinary Items -- n/m $ (0.11) n/m
Discontinued Operations $ (1.18) n/m $ (1.05) n/m
Net Income $ 2.61 9% $ 2.39 70%
- -------------------------------------------------------------------------------------------------
OTHER FINANCIAL INFORMATION
Depreciation and Amortization $ 6.4 130% $ 2.8 29%
Cash Flow from Operating Activities $ 11.5 (2%) $ 11.7 239%
Cash and Cash Equivalents $ 7.3 (60%) $ 18.2 167%
Working Capital $ 69.4 (3%) $ 71.5 121%
Total Assets $ 296.0 74% $ 170.6 103%
Total Liabilities $ 150.8 155% $ 59.1 (14%)
Stockholders' Equity $ 145.2 30% $ 111.5 628%
Average Shares Used for EPS calculation 15.3 16% 13.1 11%
</TABLE>
2
<PAGE>
<PAGE>
TO OUR SHAREHOLDERS:
THERE HAVE BEEN IMPORTANT CHANGES AT YOUR COMPANY SINCE WE LAST WROTE TO YOU.
When Cooper completes the previously announced divestiture of Hospital
Group of America (HGA), our mental health services business, we will be a pure
medical device company, competing in two attractive markets, vision care and
women's healthcare.
To update the divestiture plan: we have completed the sale of MeadowWood
Hospital to Focus Healthcare, LLC, for approximately $5 million in cash and
trade receivables. In addition, we have signed a letter of intent with Universal
Health Services, Inc., for the other three HGA properties. Universal will pay
Cooper up to $27 million in cash when the transaction closes plus up to $3
million if certain contingent events occur. The closing remains, at this
writing, subject to completion of a definitive agreement, ongoing due diligence
and certain contingencies.
HGA is now a discontinued operation and all financial data in this report
have been restated to reflect only the two medical device businesses,
CooperVision and CooperSurgical.
COOPERVISION, OUR CONTACT LENS UNIT, AND COOPERSURGICAL, OUR WOMEN'S HEALTHCARE
BUSINESS, ALSO MADE IMPORTANT TRANSITIONS THIS YEAR.
CooperVision (CVI) expanded its geographic reach by integrating Aspect
Vision Care, Ltd. of Hampshire, England, acquired in December 1997. Aspect
markets contact lenses in the United Kingdom and other European countries and
supplies CooperVision with products for the United States market. With Aspect,
CVI has significantly expanded its share of the spherical lens market-lenses
that correct near- and farsightedness and not astigmatism--which is the largest
segment of the contact lens market. At the same time, CVI continues to pursue
its goal to become the worldwide leader in high-margin specialty contact lenses,
especially toric lenses to correct astigmatism.
On October 27, 1998, The New York Stock Exchange hosted a meeting of
Cooper's Board of Directors and Management. At the meeting, the president of the
NYSE, William Johnston, presented Cooper's CEO Tom Bender with this replica of
the famous NYSE bull.
3
<PAGE>
<PAGE>
CooperSurgical (CSI), our women's healthcare business, changed its new
product development strategy. Future growth will come not only from acquisition
but also from internal new product development. Adding to its base of products
acquired since 1990, CSI introduced three new technologically advanced products,
while continuing business development activities to consolidate the in-office
women's healthcare market through acquisition.
In 1998, CVI sales grew 86% to $119.2 million--including revenue of $35
million from Aspect Vision for the eleven months it has been part of CVI.
Operating income at CVI reached $34.6 million, a 50% improvement over fiscal
1997. CSI sales grew 13% to $28 million with operating income at $2.1 million,
down 14% from last year due primarily to new product introduction expenses and
manufacturing scale-up delays.
Together, sales of Cooper's two medical device businesses reached $147.2
million, up 66% from last year with operating income of $36.7 million, before
headquarters expense, up 44%.
Cooper's diluted earnings per share from continuing operations, before tax
credits and charges for discontinued operations, were $1.51 in 1998 compared
with $1.29 in 1997, up 17%. When tax credits and discontinued operations'
charges are included, earnings per share were $2.61 in 1998 versus $2.39 in 1997
(see the "Diluted Earnings Per Share" section of the Financial Highlights
table).
The tax benefits recorded in 1998 reflect the remaining tax savings that
Cooper expects from its existing NOLs (net operating loss carry forwards).
Generally Accepted Accounting Principles require that companies with NOLs must
account for their remaining tax benefits when they determine that they expect
sustainable profit going forward. Cooper has made this determination and in the
future, will record expenses for income taxes using, initially, a tax rate of
approximately 40%. From a cash standpoint, however, it will pay only state and
foreign taxes for as long as the NOLs last. For federal tax purposes, the NOLs,
now about $180 million, will continue to shelter Cooper's federal tax liability.
As you can see in the "Diluted Earnings Per Share" section of the Financial
Highlight table, this net tax benefit was $2.28 in 1998 and $2.04 per share in
1997.
For 1999, we expect revenue and earnings from our combined medical device
businesses to grow in the range of 20% to 25%. In fact, with HGA now a
discontinued operation, Cooper's total 1999 revenue and earnings growth and its
operating margin should each be above what we would have expected with HGA
continuing as an operating unit.
4
<PAGE>
<PAGE>
FACTS AND FIGURES
ABOUT COOPER'S MEDICAL DEVICE BUSINESSES
With Cooper's imminent exit from the mental health services business,
CooperVision and CooperSurgical form a medical device company serving
two attractive healthcare segments, contact lenses and the women's
healthcare market. A summary of the financial performance of these two
businesses and their total as a medical device business follows.
REVENUE UP 66% FROM 1997
30% COMPOUND GROWTH FROM 1994
(In millions)
[GRAPH]
OPERATING INCOME(1) UP 43% FROM 1997
35% COMPOUND GROWTH FROM 1994
(In millions)
[GRAPH]
(1) Before Headquarters expense
5
<PAGE>
<PAGE>
NEW PRODUCTS AND ACQUISITIONS
COOPERVISION NEW PRODUCTS AND ACQUISITIONS 1994-1998
Recent acquisitions and new product introductions make CooperVision
a challenging competitor in every segment of the contact lens market
<TABLE>
<CAPTION>
Product Market Segment
<S> <C>
Preference Three-month planned replacement spherical lens
Preference Toric Three-month planned replacement toric lens
CooperFlex One-month planned replacement spherical lens
Aspec Vision product line Disposable-planned replacement spherical lens
Hydrasoft Toric Options Quarterly custom toric lens
Frequency 55 Toric Disposable-planned replacement toric lens
Frequency 55 Sphere Disposable-planned replacement spherical lens
Natural Touch Conventional opaque lens
Alliance Toric Disposable-planned replacement toric lens
</TABLE>
COOPERSURGICAL NEW PRODUCTS AND ACQUISITIONS SINCE 1990
During the past several years, CooperSurgical acquired new products and
businesses and built critical mass. In the future, CSI will build on this
platform through strategic acquisitions and new specialized women's healthcare
products.
<TABLE>
<CAPTION>
PRODUCT COMPANY DESCRIPTION
<S> <C>
Frigitronics Colposcopes; cryosurgery equipment
Euro-Med, Inc. Biopsy instruments; instrument cleaning systems;
gynecology instruments
RUMI Uterine manipulator with disposable tip
Unimar, Inc. Disposable endometrial biopsy device; disposable
uterine manipulator; disposable cervical PAP smear
device, disposable infertility device
Marlow Surgical Technologies Disposable intrauterine catheter; laproscopic
instrument with disposable tip; disposable balloon cannula;
micro laproscopic instruments
Hyskon solution Diagnostic and surgical aid
FemExam Test Card System Diagnostic tests for vaginal infections
Cerveillance System Digital colposcopy instrumentation and software packages
Cooper Surgical Infrared
Coagulator Non-traumatic, nonsurgical instrument to treat
genital lesions
</TABLE>
6
<PAGE>
<PAGE>
COOPERVISION
CooperVision (CVI) markets a broad range of contact lenses in North America and
Europe.
The worldwide market for contact lenses grew 11% in dollars during 1998,
according to our estimates. As it has for the past several years, the specialty
lens segment--toric lenses for astigmatism, multifocal lenses for presbyopia and
opaque lenses that can modify the eye's natural color--continued to grow
significantly faster than the spherical lens market. In the United States, we
estimate that during the first three quarters of the calendar year, the market
for all toric lenses grew 16% in value, while the sphere market was flat.
Improved toric technology and the continuing popularity of more frequently
replaced toric lens regimens continue to drive demand.
Manufacturers' revenue in the disposable-planned replacement toric market,
the fastest growing segment of the U.S. toric market, grew 42% in the first nine
months of calendar 1998, according to our latest market research. Sales of CVI's
disposable-planned replacement toric lenses in the U.S. grew 77% in fiscal 1998,
led by its well regarded Preference Toric brand, which we believe is the fastest
growing product today in the worldwide contact lens market.
Outside North America, the specialty market is not yet well-developed (see
"How CooperVision Views the Contact Lens Market"), and we plan major educational
efforts with practitioners in those markets to generate acceptance of CVI's
toric products. In Europe, Aspect introduced CVI's toric products late in fiscal
1998 and expects to expand the product line in 1999.
During 1998, CVI's "divide and conquer" strategy took shape. We plan to
offer products that can profitably meet most contact lens wearers' needs,
segmenting the market by type of vision correction required, distribution
channel, price point, geography, replacement cycle or lens material.
To implement this strategy in the U.S. toric market this year, we aimed at
the lower priced segment of the market and introduced Frequency 55 Toric, a
planned replacement lens for two-week or monthly use. Frequency 55 Toric attacks
both the toric market's leading product and the new toric lenses recently
launched by competitors, all positioned at the lower price point.
With its wider range of lens parameters compared with other low priced
torics, Frequency 55 Toric is an attractive alternative to the competitive
lenses. Moreover, even with Frequency 55 entering the lower priced segment, we
expect continued share growth with Preference Toric. Many practitioners have
learned that a few extra dollars for Preference Toric, with 15,500 lens
parameters that can fit patients more efficiently, is a good investment that
maximizes the value of their
7
<PAGE>
<PAGE>
SEGMENTS OF THE 1998 NORTH AMERICAN CONTACT LENS MARKET(1)
<TABLE>
<CAPTION>
SEGMENT ESTIMATED 1998 MARKET
($'s millions)
<S> <C>
Soft Toric Lenses
Conventional Lenses (lenses replaced annually) $ 65
Disposable-Planned Replacement (various replacement schedules) $ 104
Custom Lenses (for special prescriptions) $ 39
Total Toric Market $ 208
Soft Spherical Lenses
Conventional Lenses $ 200
Disposable-Planned Replacement $ 730
Total Spherical Lens Market $ 930
Rigid Gas Permeable Lenses $ 90
Total North American Soft Contact Lens Market Estimate $1,228
</TABLE>
(1) CooperVision Estimates
time. (For more about this, see the "Prices, parameters and manufacturing
technology" in "How CooperVision Views the Contact Lens Market").
We also introduced Hydrasoft Toric Options in 1998, a quarterly custom
planned replacement lens program for another niche: astigmatic patients who have
complex vision correction requirements.
In the U.S. spherical lens market, we describe our strategy as "comb and
brush". Comb sales representatives can easily add brushes to their line because
they call on customers who use both. We think the same way about selling
spherical lenses to customers who already fit our toric lenses. Spherical lenses
are the largest segment of the worldwide contact lens market, and the Aspect
acquisition gives us the state-of-the-art technology we need to compete
effectively in both North America and Europe with our recently introduced
Frequency 55 Sphere.
While competitors have the lion's share of the North American
disposable-planned replacement spherical lens market, we hope to capitalize on
our strong relationships with our toric customers and the clinical benefits of a
comfortable lens edge design, to help us sell Frequency 55 Sphere. In 1998, we
valued the North American market at about $930 million. We expect to capture a
relatively small but meaningful share with Frequency 55 Sphere: around 5%, or a
cumulative total of about $40 million in sales, over the next several years.
8
<PAGE>
<PAGE>
After acquiring Aspect, CVI invested $2.7 million to consolidate Aspect's
facilities and integrate the worldwide manufacturing of spherical lenses in one
location in Hampshire.
Before the rationalization of our manufacturing facilities could be
completed, U.S. demand for Frequency 55 Sphere exceeded Aspect's capacity.
Rather than lose the long-term annuity value to competitors, we decided to
accept higher costs and meet the demand, including the additional costs to hire
and train a larger work force, which we paid at premium rates. Manufacturing
yields also declined because of the lower level of experience of the new
workers.
Shifting sphere manufacturing from the Scottsville plant to the Hampshire
site in the U.K. relieved a toric lens capacity constraint that developed while
we built inventory for the introduction of Frequency 55 Toric. However, during
this transition, the new toric manufacturing lines were not yet at full
efficiency, and we incurred temporarily higher costs.
The manufacturing transition coupled with demand above our capacity in both
plants, caused CVI's gross margins to fall from 65% after the first three
quarters of 1998 to 60% in the fourth quarter. Both manufacturing facilities
have since lowered their costs through increased automation. Lens output per
employee has improved, and shift premiums are being eliminated. We expect gross
margins to return to previous levels in the 1999 fiscal year.
In addition to our manufacturing investment, our 1998 capital spending also
included construction of an expanded, up-to-date distribution center to ship
lenses manufactured in Scottsville and Hampshire. In 1999, we estimate that we
will spend about 50% less on our capital expenses than we did in 1998, so our
cash flow should improve.
With market data still showing rapid growth in the toric lens segment and a
continued shift from conventional to planned replacement toric lenses, it's
important that CVI's business keep pace. At fiscal year end, CVI's toric lens
sales accounted for 38% of its worldwide business growing 38% over 1997. In the
U.S., independent market research indicates that CVI is gaining share in every
market segment in which it competes. Worldwide, we expect most of the future
market growth from the disposable-planned replacement segment. CVI's
disposable-planned replacement toric and spherical lenses now comprise more than
75% of its business.
9
<PAGE>
<PAGE>
HOW COOPERVISION VIEWS THE CONTACT LENS MARKET
First, toric lenses.
CVI is concentrating its efforts in an attractive segment. In the U.S., toric
dollar volume is currently growing 16%, while the spherical lens market is
declining. Torics remain a proprietary segment with good margins available to
suppliers, unlike the price sensitive spherical lens segment. Astigmatic
patients have complicated vision requirements that make lens performance very
important. Our market research indicates that the practitioner's toric lens
purchasing decision is driven about 80% by how well the lens performs and 20% by
price. With spherical lenses, it's just the opposite: price drives the decision.
CVI estimates that the toric contact lens market will grow more than 20% to
about $370 million worldwide in calendar 1999--about 12% of the total market--
and reach about $1 billion in 2003--or about 20% of the market. The table to the
right shows how markets around the world will share this estimated potential.
PROJECTED GEOGRAPHIC GROWTH OF TORIC CONTACT LENSES(1)
<TABLE>
<CAPTION>
Market 1998 % of 1998 2003 % of 2003 CAGR2
(millions of $'s) Total Total
<S> <C> <C> <C> <C> <C>
North America $208 74% $462 50% 17%
Japan 15 5% 124 13% 53%
Europe 48 17% 163 17% 28%
Rest of the world 12 4% 184 20% 73%
Total toric market $283 100% $933 100% 27%
</TABLE>
(1) CooperVision estimates
(2) Compound annual growth rate
To understand these markets, we need to look at the characteristics of contact
lens wear in each of them.
North America is the most highly developed toric market. Total contact lens
penetration among those requiring vision correction is about 20%--roughly 33
million wearers--the highest in the world. Among these, 45% of myopic
(nearsighted) patients have astigmatism, but only about half of them have an
astigmatic disability that requires a toric lens to achieve clear vision. In
1998, these percentages translated to a North American toric lens potential of
about 8.3 million people. Currently, we estimate that about 3.8 million people
wear them. Clearly, there's still room to grow.
Two forces drive North American market growth: first, improvements in contact
lens technology allow more precise fits and more patients can now wear torics
successfully; second the switch from conventional lenses that are replaced once
a year to lenses replaced more frequently--daily, weekly, twice a month, monthly
or quarterly--means that more lenses will be consumed. Contact lenses generate a
continuing stream of income for suppliers while a patient remains in the market.
As long as patients continue to move to toric lenses or move from conventional
torics to disposable--planned replacement lenses, the market will continue to
grow.
Japan is the second largest contact lens market in the world. We estimate that
the penetration of contact lenses there is about 15% of the population requiring
vision correction. The incidence of both myopia and astigmatism in the Asian
population is the highest in the world, and about 75% of the myopic population
also requires an astigmatic correction. This would translate into a potential
Japanese toric market of about 6.1 million people, including a large number of
patients currently wearing hard lenses. Until recently, Japan was predominantly
a hard lens market, as concerns about chemicals from contact lens care solutions
accumulating in soft lenses prevented their wide spread acceptance. Until the
health authorities favorably reviewed the safety data, soft lenses grew slowly.
Now many brands of soft lenses are available in various replacement cycles, but
the acceptance of toric contact lenses has been slow. As Japan was a hard lens
market for so long, practitioners tend to use them for their astigmatic patients
as well, and it is difficult to change this practice.
10
<PAGE>
<PAGE>
Surprisingly, in economically well-developed Western Europe, revenue estimates
for the toric market are relatively low, and even lower in lesser-developed
Eastern Europe. Only about 8% of the Western Europeans who require vision
correction wear contact lenses and only 5% of Eastern Europeans. The reasons
behind this are primarily cultural and economic and vary from country to
country. In Western Europe, spectacles and sunglasses with fashion frames have
been preferred. In Germany, correcting astigmatism with hard lenses is still a
popular technique. Moreover, Europeans in general have less astigmatism than
North Americans do--about 35% of nearsighted patients have the condition,
according to prevalence studies.
TORIC LENS PARAMETERS AND PRICE SEGMENTS
<TABLE>
<CAPTION>
Number of
Parameters
Competitors Available Comments
- ----------- ---------- ---------
<S> <C> <C>
LOWER PRICE SEGMENT
Cooper Toric 7,776 offers flexible wearing schedule
Cooper's Frequency 55 Toric 5,832 on the market and ready to
meet emerging competition
Brand C 2,952 the current market leader
New Product B 1,300 introduced in late 1998
Brand W 750 introduced in 1997
HIGHER PRICE SEGMENT
Cooper's Preference Toric 15,500 FIPS manufacturing
Cooper's Hydrasoft Toric
Hydrasoft Toric Options potential custom lathed products
13 million for complex cases
Brand S potential a proprietary process with
13 million higher manufacturing costs and
prices than Preference Toric
</TABLE>
Before the market acceptance of our toric lenses in Japan and Europe reaches
that of North America, we will have to educate practitioners there about the
clinical and financial benefits of these products.
Prices, parameters and manufacturing technology. Understanding these three
variables is the key to learning why CVI believes it has a sustainable
competitive advantage in the toric market.
We believe that the U.S. toric lens market has two distinct and barely
overlapping price segments. In the lower priced segment, practitioners remain
willing to trade off performance in favor of a price advantage.
They can choose among several brands of lower priced toric lenses that
offer as few as 750 to as many as nearly 3,000 different fitting
parameters--combinations of 1.) "Power" that corrects for near and far defects,
2.) "Cylinder" that corrects for the astigmatism itself and 3.) "Axis," the
exact position on the toric lens that will match the location of astigmatic
defect on the cornea. CVI's recent entry in this lower priced segment--Frequency
55 Toric--has excellent prospects because it will offer over 5,800 parameters
when all lenses are available in mid-1999.
In the higher priced segment, fitters view lens performance as more important
than price. This segment is growing at the expense of the lower price segment,
as these fitters begin to recognize the clinical and financial benefits of these
lenses. CVI's Preference Toric, the market leader in this segment, offers 15,500
parameters. Practitioners can fit more Preference Toric patients correctly in
less time than when using lenses with fewer choices.
CVI's manufacturing technology allows it to compete profitably in the higher
priced segment. Historically, contact lens manufacturers have used either labor
intensive lathing, which can generate a large number of parameters, or volume
oriented lens molding where costs are low but only a limited number of
parameters can be produced profitably. CVI's patented
11
<PAGE>
<PAGE>
manufacturing process called FIPS (finished inside polymerization system)
combines the benefits of both processes--it molds the inside surface and lathes
the front surface--yielding the highest number of mass produced toric parameters
currently available at reasonable cost.
Next, spherical lenses.
In 1999, we estimate that the worldwide sphere market will grow about 10% over
1998 to nearly $2.6 billion. Most of the growth, we think, will come from
markets outside North America, led by Japan. In North America we estimate 1999
growth in spherical lenses will remain flat in dollars at about $930 million.
Longer term, we see the total sphere market growth compounding at about 11%,
reaching about $4 billion in 2003. With the Aspect acquisition, we now have
significant volume in the market for spherical lenses. In Europe and North
America together, our 1998 revenue from spheres totaled about $73 million.
With Rohto Pharmaceuticals, Ltd. as a marketing partner in Japan, CVI will
participate in the second largest spherical lens market in the world when the
health authorities have favorably reviewed our products. We're expecting Rohto
to begin selling spherical lenses in Japan during 1999. CooperVision will
manufacture the lenses and sell them to Rohto to market in Japan and throughout
the Far East. While the revenue from these sales will reflect our OEM
manufacturing status, our operating margins should reach their usual levels, as
we will not incur many of our normal marketing expenses.
Finally, a thought about laser surgery and contact lenses.
We think that Laser Vision Correction (LVC) and contact lenses are
complementary, not competitive. About 30 million people in North America wear
contact lenses, and we estimate that about 20 million former lens wearers have
dropped out of the market. They left because they no longer wanted the
inconvenience of regularly caring for their lenses or because they no longer
needed the social benefits that lenses can provide. Many left the market
because toric technology had not advanced to where it is today and their vision
was never crisp. We believe that most of the 200,000 or so patients who
underwent LVC in 1998, came from this large pool of former lens wearers. These
patients still want the benefits of contact lenses, but not the drawbacks, or
they have occupational requirements that prevent their use. Even if all 200,000
LVC patients had given up contacts for the laser treatment, the negative impact
on the 30-million wearer contact lens market would be minimal. In some cases,
there's even a positive effect. When patients learn about the recent advances in
contact lenses, especially those that correct astigmatism, and think about the
potential negatives of LVC, some want to try lenses again.
What's ahead?
We expect growth in the North American toric market to continue at its current
rate for the next several years. Improved toric technology and the continuing
popularity of more frequently replaced toric lens regimens will help push the
market ahead. We're also looking for the demand for soft toric lenses outside of
North America to pick up as practitioners begin to appreciate the benefits of
these products.
As for potential downsides, the North American spherical lens market was
disappointing in 1998, and although we have a relatively small stake in it, we
still need to determine the magnitude and duration of this market decline. While
we do not see the toric market currently declining--it's up 16% this year--we
must watch these trends closely and develop contingency plans to protect the
growth of our operating income.
- --------------------------------------------------------------------------------
Note:
THE MARKET DATA IN THIS REPORT IS FROM CVI'S "CONTACT LENS MARKET ESTIMATES
1998-2003". IF YOU'D LIKE A COPY, PLEASE CONTACT COOPER'S INVESTOR
RELATIONS DEPARTMENT.
12
<PAGE>
<PAGE>
COOPERSURGICAL
COOPERSURGICAL (CSI) MARKETS DIAGNOSTIC PRODUCTS, SURGICAL INSTRUMENTS AND
ACCESSORIES TO THE WOMEN'S HEALTHCARE MARKET.
The case for opportunity in the women's healthcare market continues to be
compelling. Like many attractive markets, it's driven primarily by favorable
demographics, and in this case, it gets an added boost from U.S. national
politics. Women's life expectancy has increased by 30 years over the last
century. In 1990, women comprised 59% of Americans over the age of 65 and 72% of
the over 85 age group. As women live longer and join the work force in
increasing numbers, industry, government and medical practitioners are
recognizing their special healthcare requirements.
Seven years ago, the National Institutes of Health, spurred in part by the
Congressional Caucus for Women's Issues, began a major undertaking called the
Women's Health Initiative. This is a $625 million study lasting 16 years that is
designed to increase the understanding of women's health during the last third
of their lives. In October 1998, Congress approved legislation to extend these
and several other women's health programs at the Centers for Disease Control and
Prevention. The bill also authorizes research on cardiovascular disease in women
at the National Heart, Lung, and Blood Institute.
The women's healthcare market is large and growing with three major
segments--pharmaceuticals, capital equipment for hospitals and large clinics and
in-office treatment. Each year, the 34,000 gynecologists in the United States
record approximately 60 million office visits, assist in 4.6 million births and
perform over two million surgical procedures. They treat conditions such as
vaginitis, excessive menstrual bleeding, cancer and its precursors,
non-malignant fibroid tumors and endometritis (an inflammation of the uterine
lining). With the recent emphasis on preventive care, many managed care
organizations now routinely reimburse common screening services such as PAP
smears, osteoporosis evaluations and mammography. The cost pressures of managed
care continue to move procedures from the hospital to the physician's office,
and many women--some estimates are as high as 55% of women--now use their
gynecologist as their general practitioner.
CSI primarily targets the in-office practice where physicians screen,
diagnose and treat the most commonly occurring gynecological conditions such as
vaginitis. CSI also provides products for hospitals and clinics (including
products for minimally invasive procedures) and reproductive medicine. In each
of these, our strategy is to identify the most frequently performed procedures
and surround physicians with the products used to do them.
Historically, CSI has attempted to consolidate the in-office women's
healthcare products market through acquisition. Since 1990, it has acquired nine
companies or product lines, and its 1998 revenue of $28 million came primarily
from these acquisitions. Typically, CSI consolidates an
13
<PAGE>
<PAGE>
TESTING FOR VAGINAL INFECTIONS
"No longer will physicians have to rely on costly laboratory tests or access to
a microscope to diagnose bacterial vaginosis. The FemExam pH and Amines TestCard
improves office testing by saving time and eliminating the need for in-office
equipment."
Dr. Mark Newman,
an investigator for the U.S. Centers for Disease Control and Prevention and a
maternal medicine specialist investigator.
VAGINAL INFECTIONS: HOW PREVALENT ARE THEY?
Based on data from the Centers for Disease Control and Prevention
and the National Disease and Therapeutic Index.
<TABLE>
<CAPTION>
Number Reported Estimated Actual Annual
Infection in 1996 Incidence (Number of Cases)
- --------- --------------- ---------------------------
<S> <C> <C>
BACTERIAL
Gonorrhea 325,883 up to 800,000
Chlamydia 490,080 up to 4 million
Syphilis 52,995 N/A
Chancroid 386 N/A
VIRAL
Human papillomavirus virus 180,000 up to 1 million
office visits
Herpes simplex 210,000 up to 500,000
office visits
OTHER
Trichomoniasis 250,000 up to 3 million
office visits
Other vaginitis
(largely bacterial vaginosis
vulvovaginal candidiasis,
i.e. yeast) 3.5 million N/A
office visits
</TABLE>
SOURCE: NYIRJESY, M.D., PAUL, "MANAGING CHRONIC VAGINITIS" OBG MANAGEMENT, MAY
1998. THE TABLE WAS ADAPTED FROM A PRESENTATION BY JOHN M. DOUGLAS, M.D.,
DIRECTOR OF STD CONTROL, DENVER PUBLIC HEALTH DEPARTMENT, "CARING FOR WOMEN WITH
VAGINAL INFECTIONS," A NATIONAL SATELLITE VIDEOCONFERENCE PRESENTED BY THE
NATIONAL NETWORK OF STD/HIV PREVENTION TRAINING CENTERS, MARCH 12,1998.
The diagnostic technology on the FemExam pH and Amines TestCard is con- tained
on a disposable card that is about the size of a credit card (shown half-size on
the left). It is designed to replace the costly, subjective and inconvenient
testing practices currently used. It provides accurate, definitive indications
of elevated pH (pH greater than or equal to 4.7) and detects the presence of
amines, which together, along with other symptoms, indicate that bacteria are
present. Industry estimates of the potential for vaginitis testing approach 125
million tests annually.
Today, physicians diagnose bacterial vaginosis using a combination of pH
measurement, subjective vaginal fluid amine evaluation, microscopy and symptom
evaluation. The FemExam pH and Amines Test Card does not require a culture,
microscopic evaluation or capital equipment and provides almost immediate
results. Collecting vaginal fluid with a cotton swab and wiping it across the
reagent portion of the card performs the tests. Clinical studies show that the
FemExam pH and Amines TestCard, when used in conjunction with clinical
impressions can accurately detect bacterial vaginosis. It is not only equivalent
to the standard measurement criteria currently used, but it also can accurately
predict when vaginosis is not present 97% of the time.
Eventually, CSI plans to introduce a series of test cards for other vaginal
infections. The primary target markets are Trichomoniasis and yeast infection.
The adjacent table indicates the large market potential for the diagnosis of
vaginal infections.
NOTE:
"OPTIMAL DIAGNOSIS OF VAGINITIS," A SUPPLEMENT TO THE NOVEMBER 1998 EDITION
OF OBG MANAGEMENT IS AVAILABLE ON REQUEST FROM COOPER'S INVESTOR RELATION
DEPARTMENT. IT REVIEWS CURRENT TRENDS IN THE DIAGNOSIS OF VAGINITIS.
14
<PAGE>
<PAGE>
acquired company's operations, including manufacturing, into its Connecticut
facility within sixty days. This generates significant economies of scale that
eventually boost margins. These acquisitions gave CSI the financial "critical
mass" to allow it to introduce its own proprietary new products.
One of these is the innovative digital colposcopy system, Cerveillance
Scope, introduced in May 1998. Using Cerveillance, physicians can examine the
cervix and then document, store and recall digital images of their findings.
Cerveillance sales to date are meeting expectations.
Another promising product introduced this year is the CooperSurgical
InfraRed Coagulator, a device that creates infrared energy for contact
coagulation of condylomas (genital lesions). Infrared coagulation is a simple,
safe, rapid and exact technique that can be used on an outpatient basis without
special training for physicians.
CSI also introduced the FemExam pH and Amines TestCard in 1998. It is the
first in a planned series of point-of-care diagnostic products in its FemExam
Test Card System. This product can improve the quality of the information that
practitioners now have to diagnose vaginitis, the most common gynecological
condition presenting in the physicians' office, and bacterial vaginosis (BV),
the most prevalent form of vaginitis. When not treated, BV has been associated
with amniotic fluid infections, premature rupture of the amniotic sac, pre-term
and low birth weight infants, endometritis and post-surgical complications.
While early acceptance of this first FemExam card has been below our
expectations due to yet unanswered questions about its medical economic benefit,
we continue to believe that the FemExam System is a breakthrough technology. The
slower than expected early sales do not change our long-term view of its
potential.
The FemExam pH and Amines TestCard is more objective than current testing
practices and can save time, thus improving diagnostic accuracy and practice
economics. We have begun formal cost benefit studies and programs to raise the
third-party reimbursement level for the product. We have lowered our revenue
expectations for 1999, but this slower ramp-up will not impact operating income,
as 1999's planned marketing expenses have also been lowered.
With CSI's new products and selective acquisitions, our objective is to
double revenue to about $60 million in the next three years and then to grow it
at twenty percent per year in the next five-year period.
15
<PAGE>
<PAGE>
COOPER GOING FORWARD
WE STRONGLY BELIEVE THAT OUR STRATEGIES FOR OUR VISION CARE AND WOMEN'S
HEALTHCARE BUSINESSES CAN ALLOW US TO CAPTURE AN EXPANDING SHARE OF THESE TWO
ATTRACTIVE MEDICAL DEVICE MARKETS OVER THE COMING YEARS.
Our success, as always, depends on the hard work of our employees and our
continuing commitment to shareholder value. We look forward to the challenges
and opportunities of 1999.
We also want to thank the many loyal Cooper shareholders that remained
confident in our future throughout the dramatic decline in the market for small
capitalization stocks during 1998. We are confident that Cooper's outlook for
1999 and beyond will reward your patience.
/s/ ALLAN E. RUBENSTEIN, M.D.
- -----------------------------
ALLAN E. RUBENSTEIN, M.D.
Chairman of the Board
/s/ A. THOMAS BENDER
- -----------------------------
A. THOMAS BENDER
President and Chief Executive Officer
January 27, 1999
16
<PAGE>
<PAGE>
INDEX TO FINANCIAL INFORMATION
<TABLE>
<S> <C>
FIVE YEAR FINANCIAL HIGHLIGHTS 18
TWO YEAR QUARTERLY INFORMATION 19
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS 20
MANAGEMENT'S STATEMENT REGARDING FINANCIAL REPORTING 26
INDEPENDENT AUDITORS' REPORT 27
CONSOLIDATED STATEMENTS OF INCOME 28
CONSOLIDATED BALANCE SHEETS 29
CONSOLIDATED STATEMENTS OF CASH FLOWS 30
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 32
QUARTERLY COMMON STOCK PRICE RANGE 54
</TABLE>
<PAGE>
<PAGE>
FIVE YEAR FINANCIAL HIGHLIGHTS
FIVE YEAR FINANCIAL HIGHLIGHTS
CONSOLIDATED OPERATIONS
<TABLE>
<CAPTION>
Years Ended October 31,
(In thousands, except per share amounts) 1998 1997 1996 1995 1994
<S> <C> <C> <C> <C> <C>
Net operating revenue $ 147,192 $ 88,769 $ 66,118 $ 55,296 $ 51,034
--------------------------------------------------------------
Gross profit $ 91,428 $ 61,444 $ 46,207 $ 37,747 $ 33,128
--------------------------------------------------------------
Income from continuing operations before income taxes $ 23,087 $ 16,936 $ 11,167 $ 6,121 $ (9,536)
(Benefit of) provision for income taxes (34,723) (26,735) (4,438) 43 (4,600)
--------------------------------------------------------------
Income (loss) from continuing operations before
extraordinary item 57,810 43,671 15,605 6,078 (4,936)
Discontinued operations, net of taxes:
Income before extraordinary item 4,336 4,719 998 (5,963) 239
Loss from disposal (22,300) (18,000) -- -- --
Extraordinary item -- (469) -- -- --
--------------------------------------------------------------
(17,964) (13,750) 998 (5,963) 239
--------------------------------------------------------------
Income (loss) before extraordinary item 39,846 29,921 16,603 115 (4,697)
Extraordinary item, net -- 1,461 -- -- --
--------------------------------------------------------------
Net income (loss) 39,846 31,382 16,603 115 (4,697)
Less, preferred stock dividends -- -- -- -- 89
--------------------------------------------------------------
Net income (loss) applicable to common stock $ 39,846 $ 31,382 $ 16,603 $ 115 $ (4,786)
--------------------------------------------------------------
Diluted earnings (loss) per share:
Continuing operations $ 3.79 $ 3.33 $ 1.32 $ 0.52 $ (0.49)
Discontinued operations (1.18) (1.05) 0.09 (0.51) 0.02
Extraordinary item, net -- 0.11 -- -- --
--------------------------------------------------------------
Earnings (loss) per share $ 2.61 $ 2.39 $ 1.41 $ 0.01 $ (0.47)
--------------------------------------------------------------
Average number of shares used to compute diluted
earnings per share 15,269 13,120 11,794 11,667 10,193
Memo diluted earnings per share data:
Income from continuing operations before income taxes $ 1.51 $ 1.29 $ 0.95 $ 0.52 $ (0.94)
--------------------------------------------------------------
- -------------------------------------------------------------------------------------------------------------------------
CONSOLIDATED FINANCIAL POSITION
- -------------------------------------------------------------------------------------------------------------------------
<CAPTION>
October 31,
(In thousands) 1998 1997 1996 1995 1994
<S> <C> <C> <C> <C> <C>
Current assets* $ 116,077 $ 100,574 $ 58,712 $ 52,185 $ 58,927
Property, plant and equipment, net 34,234 7,634 4,650 3,974 3,591
Intangible assets, net 84,308 32,274 16,864 9,901 9,669
Other assets 61,422 30,142 4,004 1,417 937
--------------------------------------------------------------
Total assets $ 296,041 $ 170,624 $ 84,230 $ 67,477 $ 73,124
--------------------------------------------------------------
Current liabilities** $ 46,701 $ 29,118 $ 26,318 $ 27,321 $ 32,391
Long-term debt 78,677 9,125 37,912 34,268 34,815
Other long-term liabilities 25,410 20,848 4,670 7,637 9,572
--------------------------------------------------------------
Total liabilities 150,788 59,091 68,900 69,226 76,778
Stockholders' equity (deficit) 145,253 111,533 15,330 (1,749) (3,654)
--------------------------------------------------------------
Total liabilities and stockholders' equity $ 296,041 $ 170,624 $ 84,230 $ 67,477 $ 73,124
--------------------------------------------------------------
</TABLE>
All prior periods have been restated to present Hospital Group of America as a
discontinued operation (see Note 3)
*Includes net assets of discontinued operations.
**Includes current installments of long-term debt
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
18
<PAGE>
<PAGE>
TWO YEAR QUARTERLY FINANCIAL DATA
TWO YEAR QUARTERLY FINANCIAL DATA
<TABLE>
<CAPTION>
- -----------------------------------------------------------------------------------------------------------------
1998
- -----------------------------------------------------------------------------------------------------------------
First Second Third Fourth
Quarter Quarter Quarter Quarter
- -----------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Net sales $ 29,384 $ 37,450 $ 39,709 $ 40,649
------------------------------------------------------
Gross profit $ 18,107 $ 24,423 $ 24,836 $ 24,062
------------------------------------------------------
Income from continuing operations before income taxes $ 4,894 $ 6,873 $ 7,429 $ 3,891
Benefit of income taxes** (449) (505) (910) (32,859)
------------------------------------------------------
Income from continuing operations 5,343 7,378 8,339 36,750
Discontinued operations, net of taxes:
Income before extraordinary item 650 1,105 1,835 746
Loss from disposal -- -- -- (22,300)
------------------------------------------------------
Loss from discontinued operations 650 1,105 1,835 (21,554)
------------------------------------------------------
Net income $ 5,993 $ 8,483 $ 10,174 $ 15,196
------------------------------------------------------
Diluted earnings per share*:
Continuing operations $ 0.35 $ 0.48 $ 0.54 $ 2.45
Discontinued operations 0.04 0.07 0.12 (1.44)
------------------------------------------------------
Net income $ 0.39 $ 0.55 $ 0.66 $ 1.01
------------------------------------------------------
Number of shares used to compute diluted
earnings per share 15,354 15,443 15,342 14,978
------------------------------------------------------
Memo diluted earnings per share data:
Income from continuing operations before income taxes $ 0.32 $ 0.45 $ 0.48 $ 0.26
------------------------------------------------------
<CAPTION>
- -----------------------------------------------------------------------------------------------------------------
1997
- -----------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Net sales $ 17,027 $ 20,630 $ 24,951 $ 26,161
------------------------------------------------------
Gross profit $ 11,996 $ 14,526 $ 16,674 $ 18,248
------------------------------------------------------
Income from continuing operations before income taxes $ 2,630 $ 3,714 $ 4,658 $ 5,934
Benefit of income taxes** (422) (455) (1,063) (24,795)
------------------------------------------------------
Income from continuing operations before
extraordinary item 3,052 4,169 5,721 30,729
Discontinued operations, net of taxes:
Income before extraordinary item 258 1,204 1,465 1,792
Loss from disposal -- -- -- (18,000)
Extraordinary item -- -- -- (469)
------------------------------------------------------
Loss from discontinued operations 258 1,204 1,465 (16,677)
------------------------------------------------------
Income before extraordinary item 3,310 5,373 7,186 14,052
Extraordinary item, net -- -- -- 1,461
------------------------------------------------------
Net income $ 3,310 $ 5,373 $ 7,186 $ 15,513
------------------------------------------------------
Diluted earnings per share*:
Continuing operations $ 0.26 $ 0.34 $ 0.44 $ 2.02
Discontinued operations 0.02 0.10 0.11 (1.10)
Extraordinary item -- -- -- 0.10
------------------------------------------------------
Net income $ 0.28 $ 0.44 $ 0.55 $ 1.02
------------------------------------------------------
Number of shares used to compute diluted
earnings per share 11,921 12,243 13,012 15,249
------------------------------------------------------
Memo diluted earnings per share data:
Income from continuing operations before income taxes $ 0.22 $ 0.30 $ 0.36 $ 0.39
------------------------------------------------------
</TABLE>
All prior periods have been restated to present Hospital Group of America as a
discontinued operation (see Note 3)
*The sum of earning per share for the four quarters is different from the full
year amount as a result of computing the quarterly and full year amounts on the
weighted average number of common shares outstanding in the respective periods.
**Includes a tax benefit of $33.3 million and $25 million for the reduction of
the valuation allowance against the deferred tax assets in the fourth quarters
of fiscal 1998 and 1997, respectively.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
19
<PAGE>
<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Note numbers refer to the "Notes to Consolidated Financial Statements" of the
Company beginning on page 32 of this report.
RESULTS OF OPERATIONS
Comparison of each of the fiscal years in the three year period ended October
31, 1998.
NET SALES
Consolidated net sales grew 66% in 1998 and 34% in 1997.
Net sales of the Company's CooperVision ("CVI") and CooperSurgical ("CSI")
business units have shown consistent growth over the three-year period:
<TABLE>
<CAPTION>
(In thousands) 1998 vs. 1997 1997 vs. 1996
<S> <C> <C> <C> <C>
BUSINESS UNIT
CVI $55,197 86% $15,121 31%
CSI $ 3,220 13% $ 7,536 44%
</TABLE>
1998 vs. 1997
Net sales of CVI products increased primarily due to the acquisition of Aspect
Vision Care Limited ("Aspect") (see Note 2) and sales growth achieved in planned
replacement contact lenses in North America. The acquisition of Aspect accounted
for 63% of the sales growth and represented approximately 29% of CVI's 1998
sales. In North America, sales of disposable-planned replacement toric lenses
grew by approximately 74%, and sales of disposable-planned replacement spherical
lenses grew approximately 79%. Sales of toric lenses to correct astigmatism,
CVI's leading product group, grew 38% for the year and accounted for 38% of
CVI's sales. In March 1997, the Company acquired Natural Touch, a line of
opaque, cosmetic contact lenses that contributed $5.4 million to 1998 sales.
These increases were partially offset by anticipated declines in sales of mature
product lines.
In February 1998, CVI introduced the Frequency 55 disposable-planned
replacement spherical lens in the United States. The worldwide market for
disposable-planned replacement spherical lenses represents about 60% of the
total worldwide contact lens market.
In May 1998, CVI introduced two new toric products: Hydrasoft Toric
Options, a custom planned replacement toric lens for astigmatic patients with
complex corrections, and Frequency 55 Toric, a planned replacement lens designed
for two-week or monthly replacement, positioned in the low-priced segment of the
disposable-planned replacement toric market.
The Company believes that CVI is well-positioned to compete successfully in
the contact lens market, particularly with its Preference and Frequency 55 line
of planned replacement lenses and its line of custom toric lenses.
At CSI, net sales increased by 13% principally due to sales of Marlow
Surgical Technologies, Inc. ("Marlow") products, acquired in April 1997 and
Hyskon, a hysteroscopy fluid used by gynecologists in certain surgical
procedures, acquired in December 1997.
CSI introduced three new product lines at the 1998 meeting of the American
College of Obstetricians and Gynecologists:
The Cerveillance Scope, an instrument that uses digital imaging and
proprietary software to provide enhanced visualization and documentation in
examinations of the cervix.
The CooperSurgical Infrared Coagulator, an instrument to perform a
nonsurgical, noninvasive procedure to treat genital lesions in the
physician's office. This technique coagulates tissue without carbonization,
providing the surgeon with a smoke free environment that reduces the
possibility of contamination.
The FemExam pH and Amines TestCard, the first in a series of patented
diagnostic tests in the FemExam TestCard System that CSI recently licensed.
These tests are used, primarily in the physician's office, to rapidly and
economically screen and diagnose common vaginal infections such as
bacterial vaginosis, yeast and trichomonasis.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
20
<PAGE>
<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS
1997 VS. 1996
CVI's net sales grew 31% due primarily to increased sales of toric lenses, CVI's
leading product group, which grew by 40% and sales of the Preference spherical
product lines, which grew 22%. Also, the addition of two new products, Natural
Touch, a line of opaque, cosmetic lenses acquired in March 1997, and Encore, a
line of planned replacement lenses, increased net sales 6%.
Net sales of CSI increased 44%. Women's healthcare products grew
approximately 56%, primarily because of sales of Marlow products and Unimar
products, acquired in April 1996. The increased sales of these products were
partially offset by expected reductions in non-strategic or non-gynecologic
product sales.
COST OF SALES/GROSS PROFIT
Gross profit as a percentage of net sales ("margin") was as follows:
<TABLE>
<CAPTION>
MARGIN 1998 1997 1996
<S> <C> <C> <C>
CVI 64% 76% 77%
CSI 55% 52% 51%
Consolidated 62% 69% 70%
</TABLE>
CVI's margin declined in 1998 vs. 1997 due to the acquisition of Aspect,
whose products have lower margins, and increased sales of lower margin Natural
Touch products. Also, in the fourth quarter of 1998, CVI incurred estimated
costs of $1.7 million for rationalizing contact lens manufacturing, filling
backorders and new product start-up inefficiencies. Margins on CVI's toric and
other specialty lines of contact lenses have maintained their strong levels.
Despite the anticipated margin decrease and the additional fourth quarter costs,
CVI's gross profit grew by 57% over 1997, fueled by rapid sales growth.
CVI's margin declined in 1997 compared with 1996 due primarily to a
write-off of approximately $300,000 of inventory related to an unsuccessful
attempt to enter the over-the-counter ophthalmic pharmaceutical market in Canada
and increased sales of lower margin Natural Touch products.
CSI's margins have improved over the three-year period, reflecting the
successful implementation of programs to more efficiently manufacture Unimar and
Marlow products. In the absence of a material acquisition of lower margin
products, Management expects that new and future proprietary products, after
initial start-up phase, will command higher margins and that CSI's margins will
continue to improve.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSE ("SGA")
<TABLE>
<CAPTION>
(In thousands) 1998 1997 1996
<S> <C> <C> <C>
CVI $38,530 $23,756 $17,281
CSI 10,686 8,813 6,243
Corporate/Other 7,010 5,768 6,193
------- ------- -------
$56,226 $38,337 $29,717
</TABLE>
Consolidated SGA increased by 29% in 1997 and 47% in 1998. Over the same
periods, consolidated revenue grew 34% and 66%, respectively, resulting in
consistent improvement in the ratio of SGA to sales from 45% of sales in 1996 to
43% in 1997 and 38% in 1998.
SGA at CVI increased by 62% in 1998 and 37% in 1997. The increase in 1998
was primarily due to the Aspect acquisition. Also, in the fourth quarter, CVI
incurred an estimated $1 million in SGA related to product launches, some of
which experienced delays. The increase in 1997 resulted primarily from
investments in selling, promotion and distribution costs required by the 31%
increase in net sales, and an accrual for a potential environmental cleanup at
one of its locations (see Note 11). As a percentage of its sales, CVI's SGA was
32% in 1998, 37% in 1997 and 35% in 1996.
The 1998 and 1997 SGA increases at CSI were due primarily to the
acquisition of Marlow in 1997 and Unimar in 1996 (see Note 2).
The 1998 increase in Corporate/Other SGA was caused primarily by additional
legal costs incurred to settle certain litigations and higher headquarters
operating costs due to expanded responsibilities for international operations.
The decrease in 1997 vs. 1996 SGA was primarily due to ongoing savings realized
from reduced insurance costs and a 1995 restructuring.
RESEARCH AND DEVELOPMENT EXPENSE
Research and development expense was $1.9 million or 1% of net sales in 1998,
$1.7 million or 2% in 1997 and $1.2 million or 2% in 1996.
The current level of research and development spending is expected to
remain stable as a percentage of sales, as the
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
21
<PAGE>
<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS
Company is focusing on acquiring products that will be marketable immediately or
in the short-term, rather than on funding longer-term, higher-risk research and
development projects.
AMORTIZATION OF INTANGIBLES
Amortization of intangibles was $3.6 million in 1998, $1.6 million in 1997 and
$1 million in 1996. The increase in each year reflects the effect of acquisition
activity during the three-year period (see Note 2).
INCOME FROM OPERATIONS
As a result of the activities discussed above, income from operations improved
by $15.4 million in 1998 vs. 1996. Income from operations by business unit and
Corporate/Other was:
<TABLE>
<CAPTION>
Years Ended October 31,
(In thousands) 1998 1997 1996
<S> <C> <C> <C>
CVI $ 34,574 $ 23,101 $ 19,065
CSI 2,136 2,476 1,667
Corporate/other (7,010) (5,774) (6,462)
----------------------------------------------
$ 29,700 $ 19,803 $ 14,270
----------------------------------------------
Percent growth 50% 39%
</TABLE>
INVESTMENT INCOME, NET
Investment income, net includes interest income of $311,000, $344,000 and
$207,000 in 1998, 1997 and 1996, respectively. The decrease in interest income
in 1998 reflected the expenditure of cash to partially fund the Aspect
acquisition. Interest income increased in 1997 because of higher investment
balances primarily from cash received from the Company's follow-on offering, net
of certain debt repayments.
SETTLEMENT OF DISPUTES, NET
In 1998, the Company recorded a charge to income of $1.3 million ($1.1 million
in the fourth quarter) to settle the dispute between the Company and GT
Laboratories (see Note 11) and certain other smaller matters. In 1997, the
$104,000 credit resulted from the reversal of an accrual no longer required.
OTHER INCOME (LOSS), NET
The change in other income (loss), net from a loss of $141,000 in 1997 to income
of $561,000 in 1998, primarily related to foreign exchange transactions. In
1997, the weakness of the Canadian dollar against the U.S. dollar resulted in a
foreign exchange loss of $142,000. In 1998, the Company had a net foreign
exchange gain of $591,000, including a gain of $850,000 as a result of the U.S.
dollar amount of Pound Sterling denominated liabilities on the Company's books
being reduced by the weakening in the Pound Sterling exchange rate prior to such
liability being hedged. In 1996, the change in the foreign exchange rate was not
a material factor.
INTEREST EXPENSE
Interest expense was $6.3 million in 1998, $3.2 million in 1997 and $3.4 million
in 1996. The increase in interest expense in 1998 vs. 1997 reflects debt used to
finance a portion of the Aspect acquisition (see Note 2). The decrease in
interest expense in 1997 vs. 1996 resulted from the redemption of the Company's
10 5/8% Convertible Subordinated Reset Debentures in April 1997 and 10% Senior
Subordinated Secured Notes in September 1997.
INCOME TAXES
Details of the Company's income tax benefit for each year in the three-year
period ended October 31, 1998 are set forth in Note 5. The 1998 provision for
federal and state taxes of $933,000 and foreign provision of $131,000 and the
utilization of foreign deferred tax asset of $168,000 was offset by the
recognition of an income tax benefit of $36 million from reducing the valuation
allowance against net U.S. deferred tax assets, based on Management's belief
that the Company's future results will enable it to utilize this asset. The 1997
provision for federal and state taxes of $545,000 was offset by a reversal of
$215,000 of tax accruals no longer required and the recognition of an income tax
benefit of $27.1 million from reducing the valuation allowance against net
deferred tax assets. The 1996 provision for federal and state taxes of $325,000
was offset by a reversal of $615,000 of tax accruals no longer required and the
recognition of an income tax benefit of $4.1 million from reducing the valuation
allowance against net deferred tax assets.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
22
<PAGE>
<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS
INCOME FROM DISCONTINUED OPERATIONS
Income from discontinued operations is income derived from the Company's
Hospital Group of America, Inc. ("HGA") business unit, which was declared a
discontinued operation by the Board of Directors in October 1998 (see Note 3).
The reported income of $4.3 million, $4.7 million and $1 million for fiscal
years ended 1998, 1997 and 1996, respectively, is net of income tax expense
(benefit) of $130,000, $129,000 and ($50,000), respectively.
LOSS FROM DISPOSAL OF DISCONTINUED OPERATIONS
In 1998, the Company wrote down the net assets of HGA by $22.3 million to the
estimated fair market value of its net assets in anticipation of the sale of the
business. HGA is accounted for as a discontinued operation (see Note 3).
In 1997, $18 million was charged to discontinued operations which related
to a settlement made in 1993 with Medical Engineering Corporation (see Note 11).
EXTRAORDINARY ITEM, NET
Continuing Operations:
In 1997, the Company recorded a net extraordinary gain of $1.5 million on the
early extinguishment of a portion of its long-term debt.
Discontinued Operations:
The $500,000 charge in 1997 reflected early extinguishment of debt recorded by
HGA.
CAPITAL RESOURCES & LIQUIDITY
The Company grew significantly in 1998, primarily due to the Aspect acquisition.
Aspect provides distribution channels for CVI products in European markets and
an additional range of products for CVI to sell in North America. Aspect also
enabled CVI to enter the biweekly and monthly lens replacement market in the
U.S.--the largest segment of the U.S. contact lens market. The integration of
Aspect and the expansion of manufacturing capacity at both Aspect and CVI's
United States plants resulted in an unusually high level of capital expenditures
in 1998. The Company's investment in inventory for new products was also
unusually high in 1998. Management expects investments in both of these to
decrease in 1999.
Cash provided by operating activities totaled $11.4 million in 1998 and
$11.7 million in 1997. Pre-launch inventory buildup of $6.9 million and the
Aspect acquisition significantly reduced 1998 operating cash flow. Aspect made
over $3 million of one-time payments shortly after the acquisition, and made a
tax payment of approximately $3 million in the second quarter for its tax
liability on pre-acquisition operations.
Cash used by investing activities was $59.3 million in 1998 vs. $17.5
million in 1997. Primary uses of cash for investing activities included payments
of approximately $21.6 million for the acquisition of Aspect (see Note 2); the
Hyskon product line purchase for $2.3 million; the purchase, for $10 million, of
a 10% equity position in Litmus Concepts Inc. and an exclusive license to
distribute Litmus' FemExam TestCard System in the U.S. and Canada. It also
included capital expenditures of nearly $20 million, which included
approximately $9.5 million to increase CVI's manufacturing capacity for
disposable-planned replacement lenses. The principal uses of cash in 1997
included capital expenditures of $7.7 million, $3 million for the acquisition of
the Natural Touch line of opaque contact lenses, $4.1 million for the
acquisition of Marlow and an investment of $2.2 million in escrow funds
restricted to expansion of CooperVision's Scottsville, New York, facility.
In 1998, the Company obtained $37.3 million in cash flow from financing
activities to fund the Aspect acquisition and the other major items discussed
under investing cash flows. The financing activities primarily related to a
$21.8 million draw from the KeyBank line of credit, the Midland Bank loan of
$17.4 million, a net increase in capitalized leases of $8 million and Aspect
obtaining $4.2 million of additional debt. The Company also repaid the $4.2
million Unimar Promissory Note and $1 million of the Wesley-Jessen Promissory
Note. Financing activities included the purchase of treasury stock, which was
authorized by the Board of Directors in September 1998. At October 31, 1998 the
Company had repurchased 486,000 shares of the Company's stock at a cost of
approximately $8 million.
For the fiscal year ended October 31, 1998, the Company failed to meet one
of the financial covenants in its KeyBank credit facility and received a waiver.
KeyBank has amended the credit agreement by reducing the ratio required by such
covenant, and the Company anticipates that it will remain in compliance in the
future (see Note 6).
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
23
<PAGE>
<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS
RISK MANAGEMENT
The Company is exposed to risks caused by changes in foreign exchange,
principally Pounds Sterling denominated debt. The Company has hedged most of
this risk by entering into contracts to buy Sterling forward. The Company is
also exposed to risks associated with changes in interest rates, as the interest
rate on certain of its debt varies with the London Interbank Offered Rate. The
Company has protected itself against this risk by entering into agreements to
swap most of its variable rate debt for fixed rate debt (see Note 7).
OUTLOOK
Management believes that cash flow from operations will fund ongoing operations.
Financings may be required to fund further plant expansion in Europe, additional
purchases of the Company's common stock and other acquisitions, if completed. At
October 31, 1998, the Company had $3.6 million available under the KeyBank line
of credit. Management anticipates that additional financing would be available
when and if required.
YEAR 2000
The Year 2000 ("Y2K") problem exists today because programmers who developed
computer systems and applications over the past few decades used two digit date
codes to designate the year. This creates a problem in the year 2000 in that
many systems will recognize "00" as the year 1900 not the year 2000. Those
systems that are not fixed may abort or produce erroneous data once the year
2000 arrives.
The Company has completed an in-depth review of the financial and
operational systems at each of its business units and is implementing a Y2K
compliance program, which is expected to be substantially completed by mid-1999.
It is taking all reasonable steps to confirm that all of its critical business
systems, software and equipment that consider and process date-related
information will continue to function properly after December 31, 1999.
The Company initiated compliance programs in 1995 to modify its proprietary
software, and many of the required changes have been completed. Software that
was recently purchased requires minimal modification and the Company will ensure
that any new software purchased will be Y2K compliant. It intends to use both
internal and external resources to reprogram, or replace, and test its software
for Y2K modifications. The Company has identified a person at each of its major
operations who is responsible for Y2K compliance and has also appointed a Y2K
Compliance Officer for the corporation. The Compliance Officer reports to the
Board of Directors on the status of the Company's programs.
The Company has experienced significant growth in the past three years and
is planning to begin implementation of a broad-based Enterprise Resource
Planning ("ERP") system throughout its major CVI operations in the U.S. and the
U.K. in 1999. The new ERP system will be Y2K compliant. In any event, as part of
its contingency plan, CVI will assure that all of its existing systems are Y2K
compliant prior to the conversion to the new system. In addition, at Aspect
Vision, its recently acquired contact lens business in the U.K., plans are in
place to build additional contact lens inventory prior to the millennium to
assure there is no disruption in the flow of products to its customers.
The Company has or is currently ensuring Y2K compliance of all business
systems and does not anticipate Y2K problems with these. It also has or is
currently communicating with vendors to determine their Y2K compliance and is
not aware of third party Y2K issues that could materially affect its operations.
The Company will continue to devote adequate resources to address its Y2K
issues. However, it cannot assure that its systems and products do not contain
undetected Y2K problems, that it will not experience operating difficulties as a
result of Y2K issues or that its new systems will be implemented in time to
avoid the probability of Y2K problems. Further, it cannot assure that the
Company's assessment of suppliers and vendors will be accurate.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
24
<PAGE>
<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS
The Company has developed contingency plans to identify and mitigate
potential Y2K problems and assess their impact on its operations. These plans
will be designed to protect its assets, continue safe operations and allow any
interrupted operations to resume in a timely fashion. The Company has developed
contingency plans to respond to equipment failures, emergencies and business
interruptions. However, contingency planning for Y2K issues is complicated by
possible multiple and simultaneous incidents, which could significantly delay
efforts to respond and resume normal business. Such incidents may be outside of
the Company's control, for example if third parties, providing goods and/or
services critical to the Company's operations, do not successfully address their
own material Y2K problems.
Based on its Y2K assessment, the Company anticipates that the cost of
upgrading or replacing its programs, systems and equipment will not materially
affect its financial position. The total expenditures, including capital,
required to be Y2K compliant are currently estimated at $500,000. Approximately
$74,000 has been expended to date.
INFLATION AND CHANGING PRICES
Inflation has had little effect on the Company's operations in the last three
years.
IMPACT OF STATEMENTS OF FINANCIAL ACCOUNTING STANDARDS ISSUED BUT NOT ADOPTED
See Footnote 1 on page 32 of this report.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
25
<PAGE>
<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS
MANAGEMENT'S STATEMENT
The financial statements and other financial information in this report are
Management's responsibility. They were prepared according to generally accepted
accounting principles and, accordingly, include amounts based on Management's
informed estimates and judgments. Other financial information in this report is
consistent with that in the financial statements.
The Company's accounting systems include controls to reasonably assure that
assets are safeguarded and financial statements conform to generally accepted
accounting principles. These systems are supplemented by selecting and training
qualified personnel and by an organizational structure that provides for
appropriate separation of duties.
The Board of Directors, through its Audit and Finance Committee of three outside
directors is responsible to determine that Management fulfills its
responsibilities regarding preparation of financial statements and maintenance
of financial control over operations. The Audit and Finance Committee recommends
to the Board of Directors appointment of the Company's independent certified
public accountants subject to ratification by the stockholders. It meets
regularly with Management and the independent accountants. The independent
accountants have access to the Audit and Finance Committee without Management
present, to discuss auditing and financial reporting.
KPMG LLP has been the Company's independent certified public accountants since
1980 when the Company incorporated. KPMG provides an objective, independent
review of the fairness of reported operating results and financial position.
Their report appears on page 27.
<TABLE>
<S> <C>
/s/ A. THOMAS BENDER /s/ ROBERT S. WEISS
-------------------------- --------------------------
A. Thomas Bender Robert S. Weiss
President Executive Vice President
and Chief Executive Officer Treasurer and Chief Financial Officer
</TABLE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
26
<PAGE>
<PAGE>
INDEPENDENT AUDITORS' REPORT
INDEPENDENT AUDITORS' REPORT
THE BOARD OF DIRECTORS AND STOCKHOLDERS
THE COOPER COMPANIES, INC.:
We have audited the accompanying consolidated balance sheets of The Cooper
Companies, Inc. and subsidiaries as of October 31, 1998 and 1997 and the related
consolidated statements of income and cash flows for each of the years in the
three-year period ended October 31, 1998. These consolidated financial
statements are the responsibility of the Company's Management. Our
responsibility is to express an opinion on these consolidated financial
statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
Management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the financial position of The Cooper
Companies, Inc. and subsidiaries as of October 31, 1998 and 1997, and the
results of their operations and their cash flows for each of the years in the
three-year period ended October 31, 1998, in conformity with generally accepted
accounting principles.
/s/ KPMG LLP
San Francisco, California
December 10, 1998
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
27
<PAGE>
<PAGE>
CONSOLIDATED STATEMENTS OF INCOME
CONSOLIDATED STATEMENTS OF INCOME
<TABLE>
<CAPTION>
- -------------------------------------------------------------------------------------------------------
Years Ended October 31,
- -------------------------------------------------------------------------------------------------------
(In thousands, except per share figures) 1998 1997 1996
- -------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Net sales $ 147,192 $ 88,769 $ 66,118
Cost of sales 55,764 27,325 19,911
------------------------------------------
Gross profit 91,428 61,444 46,207
Selling, general and administrative expense 56,226 38,337 29,717
Research and development expense 1,944 1,739 1,176
Amortization of intangibles 3,558 1,565 1,044
------------------------------------------
Income from operations 29,700 19,803 14,270
------------------------------------------
Investment income, net 329 344 238
Settlement of disputes, net 1,250 (104) --
Other income (loss), net 561 (141) 80
Interest expense 6,253 3,174 3,421
------------------------------------------
Income from continuing operations before
income taxes 23,087 16,936 11,167
Add, benefit of income taxes 34,723 26,735 4,438
------------------------------------------
Income from continuing operations before
extraordinary item 57,810 43,671 15,605
Discontinued operations, net of taxes:
Income before extraordinary item 4,336 4,719 998
Loss from disposal (22,300) (18,000) --
Extraordinary item -- (469) --
------------------------------------------
(17,964) (13,750) 998
------------------------------------------
Income before extraordinary item 39,846 29,921 16,603
Extraordinary item, net -- 1,461 --
------------------------------------------
Net income $ 39,846 $ 31,382 $ 16,603
------------------------------------------
Basic earnings per share:
Continuing operations before extraordinary item $ 3.90 $ 3.42 $ 1.34
Discontinued operations (1.21) (1.07) 0.09
Extraordinary item, net -- 0.11 --
------------------------------------------
Earnings per share $ 2.69 $ 2.46 $ 1.43
------------------------------------------
Diluted earnings per share:
Continuing operations before extraordinary item $ 3.79 $ 3.33 $ 1.32
Discontinued operations (1.18) (1.05) 0.09
Extraordinary item, net -- 0.11 --
------------------------------------------
Earnings per share $ 2.61 $ 2.39 $ 1.41
------------------------------------------
Number of shares used to compute earnings per share:
Basic 14,828 12,759 11,646
------------------------------------------
Diluted 15,269 13,120 11,794
------------------------------------------
</TABLE>
See accompanying notes to consolidated financial statements.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
28
<PAGE>
<PAGE>
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
- ----------------------------------------------------------------------------------------------------------------
October 31,
- ----------------------------------------------------------------------------------------------------------------
(In thousands) 1998 1997
- ----------------------------------------------------------------------------------------------------------------
<S> <C> <C>
ASSETS
- ----------------------------------------------------------------------------------------------------------------
Current assets:
Cash and cash equivalents $ 7,333 $ 18,249
Accounts receivable, less allowances of $1,087 in 1998 and $721 in 1997 24,426 13,150
Inventories 30,349 14,921
Deferred tax asset 15,057 5,031
Net assets of discontinued operations 29,206 46,842
Prepaid expenses and other current assets 9,706 2,381
--------------------------
Total current assets 116,077 100,574
--------------------------
Property, plant and equipment at cost 45,079 16,804
Less accumulated depreciation and amortization 10,845 9,170
--------------------------
34,234 7,634
--------------------------
Goodwill and other intangibles, net 84,308 32,274
Deferred tax asset 52,754 26,182
Other assets 8,668 3,960
--------------------------
$ 296,041 $ 170,624
--------------------------
- ----------------------------------------------------------------------------------------------------------------
LIABILITIES AND STOCKHOLDERS' EQUITY
- ----------------------------------------------------------------------------------------------------------------
Current liabilities:
Notes payable $ 4,612 $--
Current installments of long-term debt 6,958 438
Accounts payable 8,393 6,561
Employee compensation and benefits 5,087 4,155
Other accrued liabilities 12,664 8,830
Accrued income taxes 8,987 9,134
--------------------------
Total current liabilities 46,701 29,118
--------------------------
Long-term debt 78,677 9,125
Other noncurrent liabilities 25,410 20,848
--------------------------
Total liabilities 150,788 59,091
--------------------------
Commitments and Contingencies (see Note 11)
Stockholders' equity
Preferred stock, 10 cents par value, shares authorized:
1,000: zero shares issued or outstanding -- --
Common stock, 10 cents par value, shares authorized:
20,000: issued: 14,912 and 14,798 at October 31, 1998
and 1997, respectively 1,491 1,480
Additional paid-in capital 251,167 249,213
Other equity (829) (731)
Accumulated deficit (98,583) (138,429)
Less:
Treasury stock at cost, 486 shares at October 31, 1998 (7,993) --
--------------------------
Stockholders' equity 145,253 111,533
--------------------------
$ 296,041 $ 170,624
--------------------------
</TABLE>
See accompanying notes to consolidated financial statements.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
29
<PAGE>
<PAGE>
CONSOLIDATED STATEMENTS OF CASH FLOWS
CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
- ------------------------------------------------------------------------------------------------
Years Ended October 31,
- ------------------------------------------------------------------------------------------------
(In thousands) 1998 1997 1996
- ------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Cash flows from operating activities:
Net income $ 39,846 $ 31,382 $ 16,603
Adjustments to reconcile net income to net cash
provided by operating activities:
Deferred income taxes (35,787) (27,065) (4,148)
Depreciation expense 4,678 2,922 2,629
Provision for doubtful accounts 1,813 2,336 1,849
Amortization expense 3,738 1,345 723
Loss from disposal of discontinued operations 22,300 18,000 --
Extraordinary item -- (992) --
Change in operating assets and liabilities excluding
effects from acquisitions:
Receivables (3,910) (7,521) (4,998)
Inventories (6,933) (3,855) (445)
Other assets (952) (356) 266
Accounts payable 1,130 2,916 166
Accrued liabilities (5,949) (4,021) (4,488)
Income taxes payable (5,104) (423) (459)
Other long-term liabilities (3,973) (3,044) (4,287)
Other 471 107 46
--------------------------------------
Cash provided by operating activities 11,368 11,731 3,457
--------------------------------------
Cash flows from investing activities:
Purchases of assets and businesses (34,298) (7,145) (4,080)
Purchases of property, plant and equipment (19,573) (7,735) (3,182)
Investment in escrow fund -- (2,216) --
Investment in options, net (5,419) -- --
Other -- (357) 756
--------------------------------------
Cash used by investing activities (59,290) (17,453) (6,506)
--------------------------------------
</TABLE>
See accompanying notes to consolidated financial statements.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
30
<PAGE>
<PAGE>
CONSOLIDATED STATEMENTS OF CASH FLOWS -- CONCLUDED
CONSOLIDATED STATEMENTS OF CASH FLOWS -- CONCLUDED
<TABLE>
<CAPTION>
- -------------------------------------------------------------------------------------------------
Years Ended October 31,
- -------------------------------------------------------------------------------------------------
(In thousands) 1998 1997 1996
- -------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Cash flows from financing activities:
Proceeds from long-term line of credit $ 36,500 $ -- $ --
Repayment of long-term line of credit (14,700) -- --
Principal payments on long-term obligations (7,603) -- --
Proceeds from long-term borrowings 29,682 3,000 1,320
Net borrowings under short-term agreements 1,011 -- --
Purchase of Treasury Stock (7,993) -- --
Net payments of other notes payable and
current long-term debt -- (112) (1,808)
Net proceeds from follow-on offering -- 50,388 --
Early retirement of debt -- (35,740) --
Repayment of line of credit, net -- -- (1,025)
Other 430 (402) 192
---------------------------------------
Cash provided (used) by financing activities 37,327 17,134 (1,321)
---------------------------------------
Effect of exchange rate changes on cash and
cash equivalents (321) -- --
Net increase (decrease) in cash and cash equivalents (10,916) 11,412 (4,370)
Cash and cash equivalents at beginning of year 18,249 6,837 11,207
---------------------------------------
Cash and cash equivalents at end of year $ 7,333 $ 18,249 $ 6,837
---------------------------------------
Supplemental disclosures of cash flow information:
Cash paid for:
Interest (net of amounts capitalized) $ 4,536 $ 4,783 $ 4,880
---------------------------------------
Income taxes $ 5,846 $ 742 $ 119
---------------------------------------
<CAPTION>
- -------------------------------------------------------------------------------------------------
1998 1997 1996
- -------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Supplemental disclosure of noncash investing
and financing activities:
Acquisitions (see Note 2):
Fair value of assets acquired $ 93,406 $ 18,574 $ 9,661
Less:
Cash acquired -- (45) (404)
Cash paid (34,298) (7,145) (4,080)
Company stock issued (1,492) (4,662) --
Notes issued (28,009) (4,500) (4,000)
---------------------------------------
Liabilities assumed and acquisition costs accrued $ 29,607 $ 2,222 $ 1,177
---------------------------------------
</TABLE>
See accompanying notes to consolidated financial statements.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
31
<PAGE>
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
General
The Cooper Companies, Inc. (the "Company"), through its major subsidiaries,
develops, manufactures and markets healthcare products, including hard and soft
daily, flexible and extended wear contact lenses, and diagnostic products and
surgical instruments and related products. In December 1997, the Company
purchased an English contact lens company (see Note 2). Intercompany
transactions and accounts are eliminated in consolidation. In October 1998, the
Company's Management and Board of Directors declared its Hospital Group of
America, Inc. ("HGA") business a discontinued operation, and prior years'
financial statements have been restated to reflect this (see Note 3).
Foreign Currency Translation
Assets and liabilities of the Company's operations located outside the United
States are translated at prevailing year-end rates of exchange. Related income
and expense accounts are translated at weighted average rates for each year.
Gains and losses resulting from the translation of financial statements in
foreign currencies into U.S. dollars are recorded in the equity section of the
consolidated balance sheet. Gains and losses resulting from the impact of
changes in exchange rates on transactions denominated in currencies other than
each reporting locations' functional currency are included in the determination
of net income or loss for each period. Net foreign exchange income (loss)
included in the consolidated statements of income for each of the years ended
October 31, 1998, 1997 and 1996 was $591,000, ($142,000) and ($13,000),
respectively.
Derivatives
The Company uses derivatives to reduce market risk from changes in foreign
exchange and interest rates. The Company generally does not use derivative
financial instruments for trading or speculative purposes. It believes that each
of the counterparties with whom it enters into forward exchange contracts and
interest rate swap agreements is financially sound and that the credit risk of
these contracts is low. The Company continually monitors its underlying market
risk exposures and believes that it can modify or adapt itshedging strategies
when needed (see Note 7).
Estimates in the Preparation of Financial Statements
The preparation of financial statements in conformity with generally accepted
accounting principles requires Management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and the disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenue and expenses during each of the reporting
periods. Actual results could differ from those estimates.
Revenue Recognition
The Company recognizes revenue net of appropriate provisions for returns when
risk of ownership has transferred to the buyer. Management believes that there
are no significant concentrations of credit risk in trade receivables.
Cash and Cash Equivalents
Cash and cash equivalents include commercial paper and other short-term income
producing securities with maturity dates of three months or less. These
investments are readily convertible to cash and are carried at cost that
approximates market value.
INVENTORIES, AT THE LOWER OF AVERAGE COST OR MARKET
<TABLE>
<CAPTION>
- --------------------------------------------------------------------------------
October 31,
- --------------------------------------------------------------------------------
(In thousands) 1998 1997
- --------------------------------------------------------------------------------
<S> <C> <C>
Raw materials $ 4,886 $ 2,748
Work-in-process 2,779 1,277
Finished goods 22,684 10,896
------------------------------
$30,349 $14,921
------------------------------
- --------------------------------------------------------------------------------
</TABLE>
PROPERTY, PLANT AND EQUIPMENT, AT COST
<TABLE>
<CAPTION>
- --------------------------------------------------------------------------------
October 31,
- --------------------------------------------------------------------------------
(In thousands) 1998 1997
- --------------------------------------------------------------------------------
<S> <C> <C>
Land and improvements $ 1,508 $ 55
Buildings and improvements 10,662 4,385
Machinery and equipment 32,909 12,364
------------------------------
$45,079 $16,804
------------------------------
- --------------------------------------------------------------------------------
</TABLE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
32
<PAGE>
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Depreciation is computed using the straight-line method in amounts
sufficient to write off depreciable assets over their estimated useful lives.
Leasehold improvements are amortized over the shorter of estimated useful life
or the period of the related lease. Buildings are depreciated over 35 to 40
years. Machinery and equipment is depreciated over 3 to 15 years, and software
is depreciated over 3 years.
Expenditures for maintenance and repairs are expensed; major replacements,
renewals and betterments are capitalized. The cost and accumulated depreciation
of depreciable assets retired or otherwise disposed of are eliminated from the
asset and accumulated depreciation accounts, and any gains or losses are
reflected in operations for the period.
Amortization of Intangibles
Amortization is provided for on all intangible assets (primarily goodwill of
$68.2 million, which represents the excess of purchase price over fair value of
net assets acquired) on a straight-line basis over periods of up to 40 years.
Accumulated amortization at October 31, 1998 and 1997 was $8.6 million and $5.1
million, respectively. The Company assesses the recoverability of goodwill and
other long-lived assets by determining whether the amortization of the related
balance over its remaining life can be recovered through reasonably expected
undiscounted future cash flows. Management evaluates the amortization periods of
intangibles to determine whether later events and circumstances warrant revised
estimates of useful lives. To date, no such adjustments have been required.
Stock-Based Compensation
The Company adopted Statement of Financial Accounting Standards ("SFAS") 123,
Accounting for Stock-Based Compensation in 1997. This statement establishes
financial accounting and reporting standards for stock-based compensation,
including employee stock option plans. As allowed by SFAS 123, the Company
continues to measure compensation expense under the provisions of Accounting
Principles Board ("APB") No. 25, Accounting For Stock Issued to Employees, and
related interpretations (see Note 9).
Statements of Financial Accounting Standards
Issued But Not Adopted
In June 1998, the Financial Accounting Standards Board ("FASB") issued Statement
of Financial Accounting Standards ("SFAS") 133 "Accounting for Derivative
Instruments and Hedging Activities," effective beginning with the first quarter
of fiscal years beginning after June 15, 1999. SFAS 133 establishes accounting
and reporting standards for derivative instruments, and hedging activities. In
accordance with SFAS 133, an entity is required to recognize all derivatives as
either assets or liabilities on its balance sheet and measure those instruments
at fair value. SFAS 133 requires that changes in the derivative's fair value be
recognized currently in earnings unless specific hedge accounting criteria are
met, in which case gains and losses on the hedging instrument can offset related
results on the hedged item in the income statement. The Company will adopt SFAS
133 in the first quarter of fiscal 2000. Under current generally accepted
accounting principles, the Company may avail itself of hedge accounting for its
forward exchange contracts. Hedge accounting allows the Company to offset the
amounts due to and from the counterparty to the contract on its consolidated
balance sheet. Under FAS 133, forward exchange contracts will not qualify for
hedge accounting and, accordingly, the Company would then be required to include
both the receivable and the payable on its consolidated balance sheet, possibly
increasing its assets and liabilities materially.
In February 1998, the FASB issued SFAS 132 "Employers' Disclosures About
Pensions and Other Postretirement Benefits." SFAS 132 is effective for fiscal
years beginning after December 15, 1997. Restatement of disclosures for earlier
periods presented is generally required. The Statement revises disclosures about
pension and other postretirement benefit plans but does not alter the
measurement or recognition of those plans. The Company will adopt SFAS 132 as
required in the footnotes to its fiscal 1999 financial statements. Because SFAS
132 is a disclosure only Statement, Management believes adoption will have no
impact on the Company's financial position, results of operations or cash flows.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
33
<PAGE>
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
In June 1997, the FASB issued SFAS 131 "Disclosures About Segments of an
Enterprise and Related Information" which will be effective for financial
statements for periods beginning after December 15, 1997, and establishes
standards for disclosures about segments of an enterprise. The Company will make
the required disclosures under SFAS 131 beginning with its consolidated
financial statements for the year ending October 31, 1999, including the
restatement of prior years. As SFAS 131 is a disclosure document only,
Management believes adoption will not have any impact on the Company's earnings
or cash flows.
In June 1997, the FASB issued SFAS 130 "Reporting Comprehensive Income"
which will be effective for financial statements for fiscal years beginning
after December 15, 1997. It establishes standards for reporting and displaying
comprehensive income and its components in a full set of general purpose
financial statements. The Company will report comprehensive income as required
beginning with its interim financial statements for its first quarter of fiscal
1999. Upon adoption, reclassification of comparative financial statements for
prior periods to reflect application of the provisions of SFAS 130 is required.
The Company does not expect that the adoption of this statement will have any
impact on its financial position or results of operations.
NOTE 2.
ACQUISITIONS
Litmus Acquisition
In February 1998, the Company purchased, for approximately $10 million in cash,
a 10% equity position in Litmus Concepts Inc. and received an exclusive license
to distribute Litmus' FemExam TestCard System of diagnostic tests in the U.S.
and Canada. Of the $10 million purchase price, $5 million has been allocated to
the equity investment and $5 million to the exclusive license. The Company is
accounting for its investment in Litmus on the cost basis and is amortizing the
license over 17 years. The Company agreed to annual minimum purchases. This
commitment ends when the Company purchases 20 million units of the products or
on the sixth anniversary of the agreement, whichever occurs first. Under the
terms of the agreement, if the Company does not meet the required minimum
purchases, Litmus' sole remedy is its ability to cancel the license exclusivity.
Aspect Acquisition
In December 1997, the Company, through Aspect Vision Holdings, Limited
("Holdings"), acquired Aspect Vision Care Ltd. ("Aspect"), a privately-held
manufacturer of high quality contact lenses sold primarily in the United Kingdom
and other European countries. Aspect is an English company with the Pound
Sterling as its functional currency. Holdings' functional currency is the U.S.
dollar. Aspect and Holdings are included in CooperVision, Inc. ("CVI's") results
from the date of acquisition.
The Company paid approximately $51 million at closing ($20 million in cash,
38,000 shares of the Company's common stock with a value of $1.5 million and $28
million in 8% five-year notes to the selling shareholders) and will pay an
additional amount after approximately three years based Aspect's performance
over that period. The minimum amount of the additional payment of 'L'5 million
(approximately $8 million at acquisition) has been discounted at a rate of 8%
and will accrete over approximately three years. The $20 million cash payment
made at acquisition was partially financed under the Company's $50 million line
of credit (see "Midland Bank" Note 6) and cash then on hand. The acquisition has
been accounted for as a purchase. Based on an independent valuation report, the
excess of purchase price over net assets acquired has been recorded at $44.9
million and is being amortized over 40 years, and other intangibles of $3.5
million are being amortized over periods from 10 to 30 years.
Following the acquisition, certain of the selling shareholders became
employees of the Company. As of October 31, 1998 approximately $27.6 million of
the five-year notes, and the minimum contingent payments, owed by the Company in
connection with the acquisition are payable to these employees or members of
their immediate family. None of these employees is an officer of the Company.
For the year ended October 31, 1998 the Company's consolidated income statement
included $2 million of interest expense paid or payable to these individuals and
$2.3 million of royalty expense paid or payable to them.
In connection with the Aspect acquisition, the Company agreed to make
quarterly royalty payments from 5% to 7 1/2% on sales of certain
Aspect-manufactured products, with a minimum royalty for five years of 'L'1
million a year. The balance of royalty payable under the agreement was $656,000
at October 31, 1998.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
34
<PAGE>
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The following unaudited pro forma statements present consolidated condensed
results of operations for the years ended October 31, 1998, and 1997, as if
Aspect had been acquired at the beginning of each period. The unaudited pro
forma information is not indicative of either the results of operations that
would have occurred if Aspect had been purchased during the periods presented or
of future results of the combined operations.
<TABLE>
<CAPTION>
- --------------------------------------------------------------------------------
Years Ended October 31,
- --------------------------------------------------------------------------------
(In thousands, 1998 1997
except per share figures) Pro Forma Pro Forma
- --------------------------------------------------------------------------------
<S> <C> <C>
Net operating revenue $150,493 $126,637
------------------------------
Net income $ 40,114 $ 31,278
------------------------------
Shares outstanding for:
Basic EPS 14,845 12,797
------------------------------
Diluted EPS 15,286 13,158
------------------------------
EPS:
Basic $ 2.70 $ 2.44
------------------------------
Diluted $ 2.62 $ 2.38
------------------------------
- --------------------------------------------------------------------------------
</TABLE>
Natural Touch'r' Acquisition
In March 1997, the Company acquired the United States rights to Natural Touch, a
line of opaque, cosmetic contact lenses, from Wesley-Jessen Corporation ("W-J")
for $7.5 million ($3 million in cash and a $4.5 million promissory note, $4
million of which was repaid) plus an ongoing royalty ranging from 3% to 8% per
annum on sales of Natural Touch products other than those supplied by W-J. The
Company recorded intangible assets of $8 million for the patents, trademarks and
distribution rights, which are being amortized over 7 to 15 years.
A subsidiary of W-J currently manufactures and supplies the Company with
Natural Touch products. A divestiture order issued by the Federal Trade
Commission (the "FTC") in connection with the Natural Touch acquisition requires
the Company to either develop its own manufacturing capabilities or to find a
suitable third-party manufacturer. The FTC could require the Company to divest
the Natural Touch line if it has not either developed manufacturing capabilities
that meet United States Food and Drug Administration ("FDA") approval or found a
suitable third-party manufacturer meeting FDA approval within 42 months from the
acquisition date.
Marlow Acquisition
In April 1997, the Company acquired Marlow Surgical Technologies, Inc.
("Marlow"), a women's healthcare products company, for approximately $3.2
million in cash, liquidation of $900,000 of Marlow debt and 144,800 shares of
the Company's common stock valued at $2.9 million at closing. As part of the
acquisition, the Company agreed to issue an additional $500,000 of its common
stock (valued as of the closing) on the third anniversary of the closing,
subject to reduction by the amount of any obligations of the seller to indemnify
the Company in connection with the acquisition. Also, the Company has guaranteed
that the total value of the shares of its common stock issued or to be issued in
the acquisition (valued at $3.4 million in total at closing) will appreciate by
$1.3 million by the third anniversary of the acquisition. This guarantee has
been included in the purchase price, with a corresponding credit to additional
paid-in capital. The acquisition has been accounted for as a purchase, with $8.4
million of goodwill, which is being amortized over 20 years.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
35
<PAGE>
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Unimar Acquisition
In April 1996, the Company acquired Unimar, Inc., a leading provider of
specialized disposable medical devices for women's healthcare, for $8 million in
cash and notes. Goodwill has been recorded at $7.8 million, which is being
amortized over 20 years. As part of the acquisition, the Company granted a
warrant to purchase 83,333 shares of the Company's common stock for $11.375 per
share. The warrant is valued at $231,000. The exercise period of the warrant is
from April 11, 1999 to June 10, 1999. The number of shares and the exercise
price per share are subject to adjustment as provided in the warrant.
NOTE 3.
DISCONTINUED OPERATIONS
In October 1998, the Company's Board of Directors declared the Company's HGA
business unit a discontinued operation. Prior periods' financial statements have
been restated to show HGA's net earnings as income (loss) from discontinued
operations net of tax expense (benefit) of $130,000, $129,000 and ($50,000) for
1998, 1997 and 1996, respectively, and its net assets have been restated to net
assets of discontinued operations.
HGA's patient revenues were $55.5 million, $52.7 million and $43 million
for fiscal years ended October 31, 1998, 1997 and 1996, respectively. Net assets
of discontinued operations at October 31, 1998 consisted primarily of patient
receivables, net property, plant and equipment, net of accounts payable and
accrued liabilities, including a $22.3 million reserve for the estimate of the
divestiture loss.
In the fourth quarter of 1998, the Company recorded a charge reflecting its
estimate of the ultimate loss on this divestiture of $22.3 million, or $1.49 per
diluted share. The Company has signed two agreements to sell the assets of HGA
in two separate transactions. In January 1999, the Company sold the MeadowWood
hospital property of its HGA business unit to Focus Healthcare, LLC. The Company
will net approximately $5 million in cash and trade receivables. The closing is
subject to customary closing conditions. Under the second transaction, a
nonbinding letter of intent, Universal Health Services, Inc. ("UHS") will pay
the Company $27 million in cash for three of its facilities when the transaction
closes plus up to $3 million if certain contingent events occur. The nonbinding
letter of intent is subject to execution of a definitive agreement and
satisfaction of closing conditions, including regulatory approval. The Company
expects that the transaction with UHS will be completed within the first half of
fiscal 1999.
NOTE 4.
EARNINGS PER SHARE
The Company adopted SFAS 128, "Earnings Per Share" in the first quarter of 1998.
This statement requires that earnings per share ("EPS") be determined using the
weighted average number of common shares outstanding for Basic EPS, and then
outstanding dilutive stock warrants and stock options are added to determine
Diluted EPS. All prior period EPS amounts have been restated in accordance with
SFAS 128.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
36
<PAGE>
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
<TABLE>
<CAPTION>
- ----------------------------------------------------------------------------------------------------
Years Ended October 31,
- ----------------------------------------------------------------------------------------------------
(In thousands, except per share figures) 1998 1997 1996
- ----------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Income from continuing operations
before extraordinary item $ 57,810 $ 43,671 $ 15,605
Discontinued operations, net of income taxes (17,964) (13,750) 998
------------------------------------------
Income before extraordinary item 39,846 29,921 16,603
Extraordinary item, net of income taxes -- 1,461 --
------------------------------------------
Net income $ 39,846 $ 31,382 $ 16,603
------------------------------------------
- ----------------------------------------------------------------------------------------------------
BASIC:
- ----------------------------------------------------------------------------------------------------
Weighted average common shares 14,828 12,759 11,646
Basic earnings per common share:
Continuing operations before extraordinary item $ 3.90 $ 3.42 $ 1.34
Discontinued operations (1.21) (1.07) 0.09
Extraordinary item -- 0.11 --
------------------------------------------
Basic earnings per share: $ 2.69 $ 2.46 $ 1.43
------------------------------------------
- ----------------------------------------------------------------------------------------------------
DILUTED:
- ----------------------------------------------------------------------------------------------------
Weighted average common shares 14,828 12,759 11,646
------------------------------------------
- ----------------------------------------------------------------------------------------------------
ADD:
- ----------------------------------------------------------------------------------------------------
Dilutive warrants 56 62 28
Dilutive options 385 299 120
------------------------------------------
Effect of dilutive securities 441 361 148
------------------------------------------
Diluted weighted average common shares 15,269 13,120 11,794
------------------------------------------
Diluted earnings per share:
Continuing operations before extraordinary item $ 3.79 $ 3.33 $ 1.32
Discontinued operations (1.18) (1.05) 0.09
Extraordinary item -- 0.11 --
------------------------------------------
Diluted earnings per share: $ 2.61 $ 2.39 $ 1.41
------------------------------------------
- ----------------------------------------------------------------------------------------------------
</TABLE>
In the years ended October 31, 1998, 1997 and 1996, options to purchase 571,250
shares at $36.00 - $62.21 per share, 340,000 shares at $26.00 - $35.09 per share
and 150,000 shares at $14.50 per share of common stock, respectively, were
excluded from the computation of diluted earnings per share because they were
antidilutive.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
37
<PAGE>
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 5.
INCOME TAXES
The income tax provision (benefit) related to income from all operations in the
consolidated statements of income consists of:
<TABLE>
<CAPTION>
- --------------------------------------------------------------------------------
Years Ended October 31,
- --------------------------------------------------------------------------------
(In thousands) 1998 1997 1996
- --------------------------------------------------------------------------------
<S> <C> <C> <C>
From continuing operations $(34,723) $(26,735) $(4,438)
From discontinued operations 130 129 (50)
------------------------------------------
$(34,593) $(26,606) $(4,488)
------------------------------------------
- --------------------------------------------------------------------------------
</TABLE>
The income tax provision (benefit) related to income from continuing operations
in the consolidated statements of income consists of:
<TABLE>
<CAPTION>
- -------------------------------------------------------------------------------
Years Ended October 31,
- -------------------------------------------------------------------------------
(In thousands) 1998 1997 1996
- -------------------------------------------------------------------------------
<S> <C> <C> <C>
Current
Federal $ 462 $ 309 $ 196
State 471 21 (486)
Outside the United States 131 -- --
------------------------------------------
1,064 330 (290)
------------------------------------------
Deferred
Federal (35,955) (27,065) (4,148)
Outside the United States 168 -- --
------------------------------------------
(35,787) (27,065) (4,148)
------------------------------------------
$(34,723) $(26,735) $ (4,438)
------------------------------------------
- -------------------------------------------------------------------------------
</TABLE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
38
<PAGE>
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
A reconciliation of the provision for (benefit of) income taxes attributable to
income from continuing operations and the amount computed by applying the
federal income tax rate to income from continuing operations before income taxes
follows:
<TABLE>
<CAPTION>
- -------------------------------------------------------------------------------------------------------------
Years Ended October 31,
- -------------------------------------------------------------------------------------------------------------
(In thousands) 1998 1997 1996
- -------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Computed expected provision for taxes from
continuing operations $ 8,080 $ 7,407 $ 4,119
Increase (decrease) in taxes resulting from:
Income outside the United States subject to different
tax rates 431 193 132
Amortization of intangibles 477 394 256
State taxes, net of federal income tax benefit 306 229 70
Reversal of prior years' estimated state tax liabilities
no longer required -- (215) (615)
Utilization of net operating loss carryforwards (10,359) (7,102) (4,406)
Change in beginning-of-year valuation allowance (35,787) (27,065) (4,148)
Other, net 2,129 (576) 154
-------------------------------------------
Actual benefit of income taxes $(34,723) $(26,735) $ (4,438)
-------------------------------------------
- -------------------------------------------------------------------------------------------------------------
</TABLE>
The tax effects of temporary differences that give rise to significant portions
of the deferred tax assets and deferred tax liabilities are as follows:
<TABLE>
<CAPTION>
- ----------------------------------------------------------------------------------------------------------------
October 31,
- ----------------------------------------------------------------------------------------------------------------
(In thousands) 1998 1997
- ----------------------------------------------------------------------------------------------------------------
<S> <C> <C>
Deferred tax assets:
Accounts receivable, principally due to allowances for doubtful accounts $ 1,492 $ 1,216
Inventories, principally due to obsolescence reserves 1,215 988
Accrued liabilities, principally due to litigation settlements and reserves,
and compensation accruals 9,327 8,906
Net operating loss carryforwards 64,355 72,579
Capital loss carryforwards -- 2,523
Tax credit carryforwards 3,715 3,123
Other 1,225 907
--------------------------
Total gross deferred tax assets 81,329 90,242
Less valuation allowance (7,073) (52,517)
--------------------------
Deferred tax assets 74,256 37,725
--------------------------
DEFERRED TAX LIABILITIES:
Plant and equipment, principally due to purchase accounting requirements (6,445) (6,512)
--------------------------
Net deferred tax assets $ 67,811 $ 31,213
--------------------------
- ----------------------------------------------------------------------------------------------------------------
</TABLE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
39
<PAGE>
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The net decrease in the total valuation allowance for the years ended
October 31, 1998, 1997 and 1996 was $45.4 million, $27.6 million and $8.5
million, respectively. In 1998, 1997 and 1996, the Company recognized an income
tax benefit of $35.8 million, $27.1 million and $4.1 million, respectively,
($33.3 million, $25 million and $4 million in the fourth quarters of fiscal
1998, 1997 and 1996, respectively) from reducing the valuation allowance based
primarily on the continued improvement in the Company's operating results and
future prospects. The recognition of the net deferred tax assets is based upon
the expected utilization of net operating loss carryforwards that the Company
believes will more likely than not be realized.
Subsequently recognized tax benefits relating to the valuation allowance as
of October 31, 1998 will be allocated to:
<TABLE>
<CAPTION>
---------------------------------------------------------
(In thousands)
---------------------------------------------------------
<S> <C>
Consolidated statements of income $3,209
Goodwill and other intangible assets 3,555
Additional paid-in capital for stock options 309
------
$7,073
------
</TABLE>
At October 31, 1998 the Company had net operating loss and tax credit
carryforwards for federal tax purposes expiring as follows:
<TABLE>
<CAPTION>
--------------------------------------------------
Year of Net Operating Tax Credits
Expiration Losses
--------------------------------------------------
(In thousands)
--------------------------------------------------
<S> <C> <C>
1998 $ -- $ --
1999 147 847
2000 -- 1,132
2001 20,045 202
2002 27,326 29
2003 1,378 330
2004 22,241 --
2005 11,006 --
2006 22,265 --
2007 22,058 --
2008 49,535 --
2009 6,553 --
2010 1,318 --
Indefinite life - 1,175
-------------------------
$183,872 $3,715
-------------------------
</TABLE>
NOTE 6.
LONG-TERM DEBT
<TABLE>
<CAPTION>
- -----------------------------------------------------------------------------------------------------
October 31,
- -----------------------------------------------------------------------------------------------------
(In thousands) 1998 1997
- -----------------------------------------------------------------------------------------------------
<S> <C> <C>
Aspect promissory notes due December 2, 2002 (see Note 2) $27,563 $ --
KeyBank line of credit 21,800 --
Midland Bank Debt 17,444 --
Aspect Vision bank loans 6,754 --
County of Monroe Industrial Development Agency ("COMIDA") Bond 2,880 2,975
Capitalized leases, interest rates from 8% to 13% maturing 1998 to 2003 8,620 916
Wesley-Jessen Corporation ("W-J") promissory note 574 1,517
Unimar 12% promissory note -- 4,155
----------------------
85,635 9,563
Less current installments 6,958 438
----------------------
$78,677 $ 9,125
----------------------
- -----------------------------------------------------------------------------------------------------
</TABLE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
40
<PAGE>
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Annual maturities of capitalized leases and other long-term debt for each of the
five years subsequent to October 31, 1998:
<TABLE>
<CAPTION>
- --------------------------------------------------------
(In thousands)
- --------------------------------------------------------
Capitalized Other Long-
Leases Term Debt
- --------------------------------------------------------
<S> <C> <C>
1999 $1,800 $ 5,158
2000 $1,521 $ 1,465
2001 $1,253 $ 2,304
2002 $1,068 $23,387
2003 $1,145 $43,592
- --------------------------------------------------------
</TABLE>
KeyBank Line of Credit
The Company completed a $50 million senior secured revolving credit facility
with KeyBank National Association ("KeyBank") in September 1997. The facility
matures September 11, 2002, with interest rates ranging from 0.5% to 2.0% over
the London Interbank Offered Rates (LIBOR) depending on certain financial
ratios. The interest rate may be floating or fixed at the Company's option. On
October 31, 1998, the effective rates ranged from 6.5% to 6.7%. The Company pays
an annual commitment fee of 0.375% on the unused portion of the revolving credit
facility. Interest is paid monthly.
KeyBank syndicated a portion of the facility to other lenders and acts as
agent for the lenders.
Terms include a first security interest in all assets of the Company.
During the term of the facility, the Company may borrow, repay and re-borrow up
to the $50 million subject to voluntary reductions. The Company has used the
KeyBank line of credit to guarantee other foreign borrowings by issuing $24.6
million of letters of credit against the line of credit, which reduced its
unused portion. At October 31, 1998, the Company had $3.6 million available.
This line of credit is guaranteed by the subsidiaries of the Company.
Mandatory prepayments will be required to repay outstanding amounts and
permanently reduce the total commitment amount available under certain
circumstances when the Company obtains additional debt or equity.
The KeyBank Line of Credit contains various covenants, including
maintenance of certain ratios and transaction limitations requiring approval of
the lenders. Certain prepayments are subject to penalties. One of the covenants
required the Company to achieve the following ratios of earnings before
interest, taxes, depreciation and amortization (as defined) to interest expense,
capital expenditures and certain other fixed charges:
<TABLE>
<CAPTION>
- -----------------------------------------------------
For the 12 Months Ended Ratio
- -----------------------------------------------------
<S> <C>
January 31, 1998 1.3:1
April 30, 1998 1.3:1
July 31, 1998 1.3:1
Thereafter 2.0:1
- -----------------------------------------------------
</TABLE>
The Company achieved this covenant for all periods except the 12 months
ended October 31, 1998. The Company received a waiver for this period from
KeyBank. In addition, KeyBank has amended the Credit Agreement by reducing the
required ratio and the method of calculating it. The Company anticipates that it
will be able to achieve the amended covenant going forward.
Midland Bank
The Aspect acquisition was partially funded by a 'L'10.5 million loan from
Midland Bank plc, due November 27, 2002. In March 1998, the Company converted
the denomination of the loan to U.S. dollars and entered into an interest rate
swap to fix the interest rate at 6.19% per annum (see Note 7). The Midland loan
is secured by a letter of credit in its favor from KeyBank National Association.
Interest on the Midland loan is 20 basis points (0.2%) over Sterling LIBOR,
adjusted monthly, and the Company pays an annual letter of credit fee of 1% of
the balance to KeyBank.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
41
<PAGE>
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Aspect Bank Loans
The balance of the loans at October 31, 1998, was $6.8 million and is secured by
certain assets of Aspect and a $4.2 million letter of credit in favor of
National Westminster Bank ("NWB") from KeyBank National Association. Loan
maturity dates range from February 1, 2000, to September 1, 2006. The interest
rate on 'L'2.5 million borrowed March 30, 1998 is 0.2625% above Sterling LIBOR.
Sterling LIBOR was 7.58% for the period of the loan. The interest rate on other
NWB loans is 1.5% above the Base Rate. The Base Rate ranged between 7.25% and
7.5% for the reporting period. Proceeds were used to repay a loan of 'L'827,000
($1.4 million), included in acquired debt, and to fund capital expenditures.
Capitalized Leases
The balance of capitalized leases at October 31, 1998, was $8.6 million. The
leases primarily relate to purchases of manufacturing equipment, both in the
U.S. and in the United Kingdom. The increase in the amount of capitalized leases
for the period was due to the expansion of the Company's manufacturing capacity.
COMIDA Bond
The COMIDA bond is a $3 million Industrial Revenue Bond ("IRB") to finance the
cost of plant expansion, building improvements and the purchase of equipment
related to CVI's Scottsville, New York, facility. The interest rate has been
fixed at 4.88%, per a Rate Swap Transaction (see Note 7). Principal is repaid
quarterly, from July 1997 to October 2012. At October 31, 1998, unutilized
proceeds of $400,000 from the IRB, which must be used for the project described,
are carried in other assets. The IRB is secured by substantially all of CVI's
rights to the facility.
KeyBank issued a letter of credit to support certain obligations under the
COMIDA bond. CVI is obligated to repay KeyBank for draws under and expenses
incurred in connection with the letter of credit, pursuant to the terms of a
reimbursement agreement, which is guaranteed by the Company. The agreement
contains customary provisions and covenants, including the maintenance of
certain ratios and levels of net worth. CVI and COMIDA have granted a mortgage
lien on the building and real estate located in Scottsville and a first lien
security interest on the equipment purchased under the bond proceeds to KeyBank
to secure payment under the reimbursement agreement.
W-J
The W-J promissory note was issued for $4.5 million, due March 17, 2001, in
connection with the acquisition of the Natural Touch product line. To date, the
Company has repaid $4 million of the principal plus associated interest.
Interest on the W-J promissory note is payable semi-annually and accrues at 12%
annually: 8% per year is payable in cash and 4% per year is payable in kind.
Unimar Promissory Note
In April 1996, Cooper Healthcare Group, Inc. (a subsidiary of the Company)
acquired Unimar, Inc. and issued a Promissory Note for $4 million due April 11,
1999. In December 1997, the note plus associated interest was paid in full.
Interest on the note was paid annually and accrued at 12% annually: 8% per year
was paid in cash and 4% per year was paid in kind.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
42
<PAGE>
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 7.
FINANCIAL INSTRUMENTS
The fair values of the Company's financial instruments, including cash and cash
equivalents, trade receivables, lines of credit, accounts payable and accrued
liabilities, approximated their carrying values as of October 31, 1998 and 1997
because of the short maturity of these instruments.
The fair value of the Company's other long-term debt approximated the
carrying value at October 31, 1998 and 1997, as the debt was refinanced or
obtained within the respective fiscal years.
DERIVATIVES
FOREIGN EXCHANGE INSTRUMENTS
The Company enters into forward exchange contracts to hedge the currency
exposure of liabilities and firm commitments denominated in foreign currencies.
Gains and losses on hedged commitments are deferred and recognized in the
Company's results of operations in the same period as the gain or loss from the
underlying transactions. As of October 31, 1998, the Company had outstanding
forward exchange contracts of $44.6 million to purchase 27.4 million British
Pounds Sterling from November 1998 through December 2002. The fair value of the
forward exchange contracts was obtained through KeyBank's Foreign Exchange
department. The fair value indicated that termination of the forward exchange
contracts at October 31, 1998 would have resulted in a $740,000 gain.
INTEREST RATE AND OTHER DERIVATIVE INSTRUMENTS
The Company has entered into interest rate swap agreements to reduce the
potential negative impact of increases in interest rates on its outstanding
variable-rate debt under the Midland Bank Loan and the Industrial Revenue Bond.
The Company recognizes in its results of operations over the life of the
contract, as interest expense, the amortization of contract premiums incurred
from buying interest rate swaps. Net payments or receipts resulting from these
agreements are recorded as adjustments to interest expense. The effect of
interest rate instruments on the Company's results of operations in fiscal year
ended October 31, 1998 was not significant. As of October 31, 1998, the Company
had two interest rate swap agreements with notional amounts totaling $20.5
million. The $17.5 million interest rate swap matures on November 27, 2002. The
$3 million interest rate swap matures on January 1, 2012. The fair value of the
swap agreements was obtained through KeyBank's Derivative department. The fair
value indicated that termination of the swap agreements at October 31, 1998
would have resulted in a $914,000 loss.
In the fourth quarter of fiscal 1998, the Company simultaneously purchased
and sold call options in the Semiconductor Index which expired in December 1998.
The index options were purchased with temporary surplus funds of approximately
$5.4 million for trading purposes. Before the end of fiscal 1998, the Company
traded substantially all of the purchase option position and a small portion of
the sell option position and entered into a similar purchase option position and
a similar sell option position having the same December 1998 expiration date. As
of October 31, 1998, the investments in the purchased and sold call option
contracts are netted because the terms of the index option contracts provide for
a right of offset. The net investment as of October 31, 1998 in the amount of
$5.4 million is recorded at fair market value as represented by the net cash
proceeds realized when the option contracts expired in December 1998 and is
included in other current assets. The transaction did not result in any material
gain or loss on the Company's financial statements.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
43
<PAGE>
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 8.
STOCKHOLDERS' EQUITY
<TABLE>
<CAPTION>
- ------------------------------------------------------------------------------------------------------------------------------------
Common Common Paid-in Accumulated Treasury
Shares Stock Capital Deficit Stock
- ------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Balance at October 31, 1995 11,576 $ 1,158 $ 183,840 $(186,414) $ --
Exercise of stock options 22 2 117 -- --
Exercise of warrants and warrant valuation 66 6 297 -- --
Restricted stock amortization and
share issuance 7 1 46 -- --
Net income -- -- -- 16,603 --
-----------------------------------------------------------------------------
Balance at October 31, 1996 11,671 1,167 184,300 (169,811) --
Exercise of stock options 36 4 260 -- --
Exercise of warrants 27 3 147 -- --
Restricted stock amortization and
share issuance 3 -- 483 -- --
Stock issued for acquisition (see Note 2) 145 14 4,648 -- --
Stock issued for 10 5/8% debenture
redemption 616 62 9,217 -- --
Follow-on offering 2,300 230 50,158 -- --
Net income -- -- -- 31,382 --
-----------------------------------------------------------------------------
Balance at October 31, 1997 14,798 1,480 249,213 (138,429) --
Exercise of stock options 75 7 419 -- --
Treasury stock purchased -- -- -- -- (7,993)
Restricted stock amortization and
share issuance 1 -- 47 -- --
Stock issued for acquisition (see Note 2) 38 4 1,488 -- --
Net income -- -- -- 39,846 --
-----------------------------------------------------------------------------
Balance at October 31, 1998 14,912 $ 1,491 $ 251,167 $ (98,583) $ (7,993)
-----------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
44
<PAGE>
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Treasury Stock
In September 1998, the Company's Board of Directors authorized the purchase of
up to one million shares of the Company's common stock ("Treasury Stock"). By
October 31, 1998, the Company had repurchased 486,000 shares of Treasury Stock
at a cost of $8 million.
Common Stock Offering
In 1997, in an underwritten follow-on stock offering, the Company sold 2.3
million shares of its common stock at $23.50 per share. The proceeds from the
offering of $50.4 million, net of underwriters discount and transaction costs of
$3.7 million, were primarily used to repay outstanding debt.
Stockholders' Rights Plan
Under the Company's stockholder rights plan, each outstanding share of the
Company's common stock carries one preferred share purchase right (a "Right").
The Rights will become exercisable only under certain circumstances involving
acquisition of beneficial ownership of 20% or more of the Company's common stock
by a person or group (an "Acquiring Person") without the prior consent of the
Company's Board of Directors. If a person or group becomes an Acquiring Person,
each Right would then entitle the holder (other than an Acquiring Person) to
purchase, for the then purchase price of the Right (currently $145, subject to
adjustment), shares of the Company's common stock, or shares of common stock of
any person into which the Company is thereafter merged or to which 50% or more
of its assets or earning power is sold, with a market value of twice the
purchase price. The Rights will expire in October 2007 unless earlier exercised
or redeemed. The Board of Directors may redeem the Rights for $.01 per Right
prior to any person or group becoming an Acquiring Person.
Other Equity
At October 31, 1998, 1997 and 1996, the Company's cumulative foreign currency
translation adjustments and deferred compensation reported in other equity were
($829,000), ($731,000) and ($326,000), respectively.
NOTE 9.
EMPLOYEE STOCK PLANS
At October 31, 1998 the Company has two stock-based compensation plans:
1998 Long-Term Incentive Plan ("1998 LTIP")
The 1998 LTIP is a vehicle for the Company to attract, retain and motivate its
key employees and consultants, who are directly linked to the profitability of
the Company and to increasing stockholder value. The 1998 LTIP was approved by
the Company's stockholders in April 1998.
The 1998 LTIP authorized either a committee consisting of three or more
individuals not eligible to participate in the 1998 LTIP or the Company's Board
of Directors to grant to eligible individuals during a five-year period, stock
options, stock appreciation rights, restricted stock, deferred stock, stock
purchase rights, phantom stock units and long-term performance awards for up to
1,000,000 shares of common stock, subject to adjustment for future stock splits,
stock dividends, expirations, forfeitures and similar events. Options generally
vest based on the Company's stock price, however, in some cases, both stock
price and time are used as criteria. As of October 31, 1998, 460,000 shares
remained available under the 1998 LTIP for future grants. No restricted shares
have been granted under the 1998 LTIP. Under a predecessor plan, the 1988 LTIP
which expired, a total of 2,060,635 shares of restricted stock and stock options
were awarded.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
45
<PAGE>
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1996 Long-Term Incentive Plan for Non-Employee
Directors ("1996 NEDRSP")
In March 1996, the Company's stockholders approved reducing the annual cash
stipend paid to Non-Employee Directors and to award grants of restricted stock
and options awarded annually at the start of each fiscal year. Specifically,
each Non-Employee Director will be awarded the right to purchase restricted
stock worth $7,500 for $0.10 per share (or $9,375 in the case of the Chairman of
the Board who is a Non-Employee Director) by January 15 of the year following
the date of the grant. Grants of restricted stock not exercised by then will
expire. The restrictions on the restricted stock will lapse when the stock
reaches certain target values or by the fifth anniversary of the date of grants.
In addition, each Non-Employee Director was granted an option to purchase shares
of the Company's common stock in fiscal 1998 and 1997 and will be granted 5,000
shares in each subsequent fiscal year (or, in the case of the Chairman of the
Board who is a Non-Employee Director, 6,250 shares in each subsequent fiscal
year) through fiscal 2000. 215,000 shares of the Company's authorized but
unissued common stock have been reserved for this. As of October 31, 1998,
117,240 shares remained available under the 1996 NEDRSP for future grants.
Restricted shares of 1,312, 3,501 and 7,393 were granted under the 1996 NEDRSP
in fiscal 1998, 1997 and 1996, respectively, and there were no restricted shares
with restrictions in place outstanding October 31, 1998.
<TABLE>
<CAPTION>
- -----------------------------------------------------------------------------------------------------------------------------------
Common stock activity under these plans:
- -----------------------------------------------------------------------------------------------------------------------------------
Years Ended October 31,
- -----------------------------------------------------------------------------------------------------------------------------------
1998 1997 1996
- -----------------------------------------------------------------------------------------------------------------------------------
Weighted Weighted Weighted
Average Average Average
Exercise Exercise Exercise
Options Price Options Price Options Price
- -----------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Outstanding at beginning
of year 929,564 $ 19.39 459,662 $ 8.90 328,841 $ 5.77
Granted 806,250 38.16 514,165 27.69 192,361 12.77
Exercised (75,017) 5.68 (36,454) 7.25 (21,755) 5.59
Forfeited -- -- (7,809) 5.78 (39,785) 3.55
-----------------------------------------------------------------------------------------------
Outstanding at end of year 1,660,797 $ 29.13 929,564 $ 19.39 459,662 $ 8.90
--------- ------ -------
Options
exercisable at year end 605,797 $ 19.99 449,564 $ 9.71 244,164 $ 6.15
Weighted-avg. fair value of
options granted during
the year $ 8.57 $ 12.32 $ 5.30
- -----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
46
<PAGE>
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The options outstanding at October 31, 1998 for the stock option plans are:
<TABLE>
<CAPTION>
Options Outstanding Options Exercisable
---------------------------------------- ------------------------
Weighted
Average Weighted Weighted
Number Remaining Average Number Average
Outstanding Contractual Exercise Outstanding Exercise
Exercise Prices at 10/31/98 Life Price at 10/31/98 Price
- --------------- ----------- ----------- -------- ----------- --------
<S> <C> <C> <C> <C> <C>
$ 1.68 5,490 0.54 $ 1.68 5,490 $ 1.68
$ 3.18-6.88 125,445 6.77 6.20 125,445 6.20
$ 7.68-16.00 280,279 7.46 13.10 230,279 12.46
$20.00-26.00 395,833 8.89 23.17 13,333 21.00
$30.69-36.91 415,750 9.13 34.98 231,250 35.34
$38.38-43.20 285,000 9.34 40.55 -- --
$51.84 85,000 9.91 51.84 -- --
$62.21 68,000 9.91 62.21 -- --
---------------------------------------------------------------------
$ 1.68-62.21 1,660,797 8.69 $ 29.13 605,797 $ 19.99
---------------------------------------------------------------------
</TABLE>
The excess of market value over $.10 per share of 1988 LTIP, 1990 NEDRSP and
1996 NEDRSP restricted shares on respective dates of grant is initially recorded
as unamortized restricted stock award compensation, a separate component of
stockholders' equity, and charged to operations as earned. Restricted shares and
other stock compensation charged against income from operations for the years
ended October 31, 1998, 1997 and 1996 was $260,000, $107,000 and $46,000,
respectively.
Pro Forma Information
As permitted by FASB 123, the Company applies APB Opinion No.25 and related
interpretations in accounting for its plans for stock issued to employees.
Accordingly, no compensation cost has been recognized for its stock option
plans. Had compensation cost for the Company's stock-based compensation plans
been determined under the fair value method included in SFAS 123, the Company's
net income and earnings per share would have been reduced to the pro forma
amounts indicated below:
<TABLE>
<CAPTION>
- ----------------------------------------------------------------------------------
(In thousands, except per share amounts) 1998 1997 1996
- ----------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Net Income As reported $39,846 $31,382 $16,603
Pro forma $34,512 $29,704 $16,487
- ----------------------------------------------------------------------------------
Basic earnings per share As reported $ 2.69 $ 2.46 $ 1.43
Pro forma $ 2.33 $ 2.33 $ 1.42
- ----------------------------------------------------------------------------------
Diluted earnings per share As reported $ 2.61 $ 2.39 $ 1.41
Pro forma $ 2.28 $ 2.29 $ 1.40
- ----------------------------------------------------------------------------------
</TABLE>
The above pro forma amounts include compensation expense for options
granted since November 1, 1995, and may not be representative of that to be
expected in future years.
The fair value of each option grant is estimated on the date of grant using
the Black-Scholes option-pricing model with the following weighted average
assumptions used for grants in 1998, 1997 and 1996: zero dividend yield;
expected volatility of 48 percent; expected option lives of 3.5 years and
risk-free interest rates of 4.8%, 6.5% and 5.9%, respectively.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
47
<PAGE>
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 10.
EMPLOYEE BENEFITS
The Company's Retirement Income Plan The Company's Retirement Income Plan (the
"Plan") covers substantially all full-time United States employees of CVI and
the Company's corporate headquarters. The Company's contributions are designed
to fund normal cost on a current basis and to fund over 30 years the estimated
prior service cost of benefit improvements (15 years for annual gains and
losses). The unit credit actuarial cost method is used to determine the annual
cost. The Company pays the entire cost of the Plan and funds such costs as they
accrue. Virtually all of the assets of the Plan are comprised of participation
in equity and fixed income funds.
Net periodic pension cost of the Plan was:
<TABLE>
<CAPTION>
- --------------------------------------------------------------------------------
Years Ended October 31,
- --------------------------------------------------------------------------------
(In thousands) 1998 1997 1996
- --------------------------------------------------------------------------------
<S> <C> <C> <C>
Service cost $ 398 $ 236 $ 256
Interest cost 664 622 598
Actual return
on assets (199) (1,446) (1,047)
Net amortization
and deferral (571) 786 488
---------------------------------------------
Net periodic
pension cost $ 292 $ 198 $ 295
---------------------------------------------
- --------------------------------------------------------------------------------
</TABLE>
The actuarial present value of benefit obligations and funded status for the
Plan was:
<TABLE>
<CAPTION>
- --------------------------------------------------------------------------------
October 31,
- --------------------------------------------------------------------------------
(In thousands) 1998 1997
- --------------------------------------------------------------------------------
<S> <C> <C>
Vested benefit obligation $ 9,352 $ 8,120
Non-vested benefit obligation 67 18
----------------------------
Accumulated benefit
obligation 9,419 8,138
Projected compensation
increases 1,046 819
----------------------------
Projected benefit obligation 10,465 8,957
Fair value of plan assets 8,824 9,012
----------------------------
Projected benefit obligation in
excess of (less than) assets 1,641 (55)
Add (Deduct):
Unrecognized net gain (401) 1,076
Prior service cost remaining to
be amortized, including
unrecognized net asset (336) (358)
----------------------------
Pension liability recognized $ 904 $ 663
----------------------------
- --------------------------------------------------------------------------------
</TABLE>
Assumptions used in developing the projected benefit obligation
were:
<TABLE>
<CAPTION>
--------------------------------------------------------------
August 31,
--------------------------------------------------------------
1998 1997
--------------------------------------------------------------
<S> <C> <C>
Discount rate on plan liabilities 7.0% 7.5%
Long-range rate of return
on plan assets 9.0% 9.0%
Salary increase rate 4.0% 4.0%
--------------------------------------------------------------
</TABLE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
48
<PAGE>
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The Company's 401(k) Savings Plan
The Company's 401(k) Savings Plan provides for the deferral of compensation as
described in the Internal Revenue Code and is available to substantially all
full-time United States employees of the Company. Employees who participate in
the 401(k) Plan may elect to have from 1% to 16% (2% to 10%, prior to October 1,
1996) of their pre-tax salary or wages (but not more than $5,000 for employees
whose salary is more than $66,000 annually for the calendar year ended December
31, 1996) deferred and contributed to the trust established under the Plan. The
Company's contribution on account of participating employees, net of forfeiture
credits, was $396,000, $218,000 and $102,000 for the years ended October 31,
1998, 1997 and 1996, respectively.
The Company's Incentive Payment Plan
The Company's Incentive Payment Plan is available to officers and other key
executives. Participants may, in certain years, receive bonuses based on
performance. Total payments earned for the years ended October 31, 1998, 1997
and 1996, were approximately $851,000, $1.8 million and $1.8 million,
respectively. The 1997 and 1996 payments included payments made to HGA
executives of $414,000 and $326,000 respectively.
NOTE 11.
COMMITMENTS, CONTINGENCIES AND PENDING LITIGATION
Total minimum annual rental obligations (net of sublease revenue of
approximately $470,000 per year through March 2000) under noncancelable
operating leases (substantially all real property or equipment) in force at
October 31, 1998 are payable in subsequent years as follows:
<TABLE>
<CAPTION>
---------------------------------
(In thousands)
---------------------------------
<S> <C>
1999 $ 3,971
2000 3,463
2001 2,828
2002 2,356
2003 2,030
2004 and thereafter 10,507
-------
$25,155
---------------------------------
</TABLE>
Aggregate rental expense for both cancelable and noncancelable contracts
amounted to $3.2 million, $3 million and $2.5 million in 1998, 1997 and 1996,
respectively.
An agreement was reached in September 1993 with Medical Engineering
Corporation ("MEC"), a subsidiary of Bristol-Myers Squibb Company, which limited
the Company's contingent liabilities associated with breast implant litigation
involving a former division of the Company (the "MEC Agreement"). The remaining
liability recorded for payments to be made to MEC under the MEC Agreement are
due on:
<TABLE>
<CAPTION>
- --------------------------------------------------------------
Other Accrued Other Noncurrent
December 31, Liabilities Liabilities
- --------------------------------------------------------------
(In thousands)
- --------------------------------------------------------------
<S> <C> <C>
1998 $2,500 $ --
1999 -- 3,000
2000 -- 3,500
2001 -- 4,000
2002 -- 4,500
2003 -- 3,000
--------------------------
$2,500 $18,000
--------------------------
- --------------------------------------------------------------
</TABLE>
Payments to MEC of $18 million beginning December 31, 1999 are contingent upon
the Company's earning net income before taxes in each fiscal year beginning with
fiscal 1999. They were recorded in the Company's financial statements in the
fourth quarter of fiscal 1997 as loss from sale of discontinued operations. They
are reflected on the balance sheet in "Other noncurrent liabilities" as
Management concluded that the payments would most likely be required. These
payments are limited to the lesser of 50% of the Company's net income before
taxes in each fiscal year on a noncumulative basis, or the amounts shown above.
Environmental
In 1997, environmental consultants engaged by the Company identified a contained
area of groundwater contamination consisting of industrial solvents including
trichloroethane ("TCA") at one of CVI's sites. In the opinion of counsel, the
solvents were released into the ground prior to the Company acquiring the
business at that site, and the area containingthese chemicals is limited. The
New York Department of
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
49
<PAGE>
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Environmental Conservation ("DEC") informed the Company on July 21, 1998 that
the site was eligible for the New York Voluntary Cleanup Program. Recently, the
Company and DEC reached agreement on a required order and scope of work that
involves additional investigation. This further investigation will ultimately
result in a state-approved remediation. The Company has accrued approximately
$500,000 for that purpose. In the opinion of Management, the cost of remediation
will not be material when considering amounts previously accrued.
Pending Litigation--GT Labs
On October 1, 1992, GT Laboratories, Inc. filed a complaint against the Company
in the United States District Court for the Northern District of Illinois
alleging that the Company had breached a supply agreement by failing to purchase
the requisite number of contact lens blanks used in the manufacture of rigid gas
permeable contact lenses. The Company denied that it had breached the contract
and asserted its right to terminate the agreement. In the interest of avoiding
further litigation costs, the parties have agreed to resolve their dispute by
way of settlement. On December 22, 1998, the parties entered into a Settlement
Agreement and Release whereby the Company agreed to pay GT Laboratories $1.3
million, $1.1 million of which was accrued in the fourth quarter, in return for
the plaintiff's release of all claims against the Company. In January 1999, the
litigation was dismissed with prejudice.
NOTE 12.
BUSINESS SEGMENT INFORMATION
The Company's operations are attributable to two business segments:
CVI, which develops, manufactures and markets a range of contact lenses,
and
CooperSurgical, Inc. ("CSI"), which develops, manufactures and distributes
diagnostic products and surgical equipment, instruments and disposables,
primarily for obstetrics and women's healthcare.
Total net sales include sales to customers as reported in the Company's
consolidated statements of income and sales between geographic areas which are
priced at terms that allow for a reasonable profit for the seller. Operating
income (loss) is total net sales less cost of sales, research and development
expenses, selling, general and administrative expenses and amortization of
intangible assets. Corporate operating loss is principally corporate
headquarters expense. Investment income, net, settlement of disputes, net, other
income (expense), net, and interest expense were not allocated to individual
businesses.
Identifiable assets are those assets used in continuing operations
exclusive of cash and cash equivalents, which are included as corporate assets.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
50
<PAGE>
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
<TABLE>
<CAPTION>
- -----------------------------------------------------------------------------------------------------------------
Information by business segment for each of the years in the three-year period ended October 31, 1998 follows
- -----------------------------------------------------------------------------------------------------------------
Corporate &
1998 CVI CSI Eliminations Consolidated
- -----------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Net revenue from non-affiliates $ 119,210 $ 27,982 $ -- $ 47,192
----------------------------------------------------------
Operating income (loss) $ 34,574 $ 2,136 $ (7,010) $ 29,700
--------------------------------------------
Investment income, net 329
Settlement of disputes, net (1,250)
Other income (expense), net 561
Interest expense (6,253)
--------------
Income from continuing operations before income taxes $ 23,087
--------------
Identifiable assets $ 143,888 $ 41,887 $ 110,266 $ 296,041
----------------------------------------------------------
Depreciation expense $ 2,307 $ 484 $ 81 $ 2,872
----------------------------------------------------------
Amortization expense $ 2,090 $ 1,468 $ -- $ 3,558
----------------------------------------------------------
Capital expenditures $ 16,941 $ 746 $ 45 $ 17,732
----------------------------------------------------------
1997
- -----------------------------------------------------------------------------------------------------------------
Net revenue from non-affiliates $ 64,007 $ 24,762 $ -- $ 88,769
----------------------------------------------------------
Operating income (loss) $ 23,101 $ 2,476 $ (5,774) $ 19,803
--------------------------------------------
Investment income, net 344
Other income (expense), net (37)
Interest expense (3,174)
--------------
Income from continuing operations before income taxes 16,936
--------------
Identifiable assets $ 43,380 $ 29,543 $ 97,701 $ 170,624
----------------------------------------------------------
Depreciation expense $ 803 $ 349 $ 79 $ 1,231
----------------------------------------------------------
Amortization expense $ 674 $ 891 $ -- $ 1,565
----------------------------------------------------------
Capital expenditures $ 3,551 $ 507 $ 74 $ 4,132
----------------------------------------------------------
1996
- -----------------------------------------------------------------------------------------------------------------
Net revenue from non-affiliates $ 48,892 $ 7,226 $ -- $ 66,118
----------------------------------------------------------
Operating income (loss) $ 19,065 $ 1,667 $ (6,462) $ 14,270
--------------------------------------------
Investment income, net 238
Other income (expense), net 80
Interest expense (3,421)
--------------
Income from continuing operations before income taxes $ 11,167
--------------
Identifiable assets $ 23,756 $ 18,089 $ 2,385 $ 84,230
----------------------------------------------------------
Depreciation expense $ 800 $ 236 $ 82 $ 1,118
----------------------------------------------------------
Amortization expense $ 314 $ 461 $ 269 $ 1,044
----------------------------------------------------------
Capital expenditures $ 1,293 $ 404 $ 54 $ 1,751
----------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------
</TABLE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
51
<PAGE>
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
<TABLE>
<CAPTION>
- -----------------------------------------------------------------------------------------------------------------
Information by geographical area for each of the years in the three-year period ended October 31, 1998 follows:
- -----------------------------------------------------------------------------------------------------------------
Eliminations
1998 United States Europe Canada & Corporate Consolidated
- -----------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
Sales to unaffiliated customers $ 102,181 $ 34,952 $ 10,059 $ -- $ 147,192
Sales between geographic areas 3,403 5,858 -- (9,261) --
------------------------------------------------------------------------------
Net sales $ 105,584 $ 40,810 $ 10,059 $ (9,261) $ 147,192
------------------------------------------------------------------------------
Operating income (loss) $ 34,134 $ 2,081 $ 495 $ (7,010) $ 29,700
------------------------------------------------------------------------------
Identifiable assets $ 105,095 $ 78,042 $ 2,638 $ 110,266 $ 296,041
1997
- -----------------------------------------------------------------------------------------------------------------
Sales to unaffiliated customers $ 79,620 $ -- $ 9,149 $ -- $ 88,769
Sales between geographic areas 3,866 -- -- (3,866) --
------------------------------------------------------------------------------
Net sales $ 83,486 $ -- $ 9,149 $ (3,866) $ 88,769
------------------------------------------------------------------------------
Operating income (loss) $ 25,981 $ -- $ (404) $ (5,774) 19,803
------------------------------------------------------------------------------
Identifiable assets $ 69,909 $ -- $ 3,014 $ 97,701 $ 170,624
1996
- -----------------------------------------------------------------------------------------------------------------
Sales to unaffiliated customers $ 57,886 $ -- $ 8,232 $ -- $ 66,118
Sales between geographic areas 5,676 -- -- (5,676) --
------------------------------------------------------------------------------
Net sales $ 63,562 $ -- $ 8,232 $ (5,676) $ 66,118
------------------------------------------------------------------------------
Operating income (loss) $ 21,127 $ -- $ (395) $ (6,462) $ 14,270
------------------------------------------------------------------------------
Identifiable assets $ 39,021 $ -- $ 2,824 $ 42,385 $ 84,230
- -----------------------------------------------------------------------------------------------------------------
</TABLE>
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
52
<PAGE>
<PAGE>
Corporate Information
BOARD OF DIRECTORS:
ALLAN E. RUBENSTEIN, M.D.
President WorldCare Imaging Services, Inc. Chairman
A. THOMAS BENDER
President and Chief Executive Officer
MICHAEL H. KALKSTEIN
Partner Graham & James
MOSES MARX
General Partner United Equities
DONALD PRESS
Executive Vice President Broadway Management Co., Inc.
STEVEN ROSENBERG
Vice President and Chief Financial Officer, Cooper Life Sciences, Inc.
ROBERT S. WEISS
Executive Vice President,
Treasurer and Chief Financial Officer
STANLEY ZINBERG, M.D.
Director of Practice Activities American College of Obstetricians and
Gynecologists
OFFICERS:
A. THOMAS BENDER
President and Chief Executive Officer and President CooperVision, Inc.
ROBERT S. WEISS
Executive Vice President,
Treasurer and Chief Financial Officer
B. NORRIS BATTIN
Vice President Investor Relations and Communications
GREGORY A. FRYLING
Vice President Corporate Development
CAROL R. KAUFMAN
Vice President of Legal Affairs, Secretary and Chief Administrative Officer
NICHOLAS J. PICHOTTA
President CooperSurgical, Inc.
STEPHEN C. WHITEFORD
Vice President and Corporate Controller
COMMITTEES OF THE BOARD:
MANAGEMENT COMMITTEE
ALLAN E. RUBENSTEIN, M.D. (Chairman)
Donald Press
AUDIT AND FINANCE COMMITTEE
STEVEN ROSENBERG (Chairman)
MICHAEL H. KALKSTEIN, STANLEY ZINBERG, M.D.
COMPENSATION COMMITTEE
MICHAEL H. KALKSTEIN
(Chairman) Donald Press
ALLAN E. RUBENSTEIN, M.D.
NOMINATING COMMITTEE
ALLAN E. RUBENSTEIN, M.D. (Chairman)
MOSES MARX
A. THOMAS BENDER, STANLEY ZINBERG, M.D.
CORPORATE OFFICES:
THE COOPER COMPANIES, INC.
10 Faraday, Irvine, CA 92618-1850
Voice: (949) 597-4700 or toll free,
1-888-822-2660, Fax: (949) 597-0662
THE COOPER COMPANIES, INC.
6140 Stoneridge Mall Rd., Suite 590
Pleasanton, CA 94588
Voice: (925) 460-3600, Fax: (925) 460-3648
PRINCIPAL SUBSIDIARIES:
COOPERVISION, INC.
10 Faraday, Irvine, CA 92618-1850
Voice: (949) 597-4700, Fax: (949) 597-0662
COOPERSURGICAL, Inc.
15 Forest Parkway, Shelton, CT 06484
Voice: (203) 929-6321, Fax: (203) 925-0135
HOSPITAL GROUP OF AMERICA, INC.
6140 Stoneridge Mall Rd., Suite 590
Pleasanton, CA 94588
Voice: (925) 460-3600, Fax: (925) 460-3648
Note: HGA was declared a discontinued operation in October 1998. Its
headquarters will close at the end of January, 1999.
COMMON STOCK PRICE RANGE:
<TABLE>
<CAPTION>
Years Ended October 31,
1998 1997
Quarter Ended High Low High Low
<S> <C> <C> <C> <C>
January 31 50 34 11/16 18 3/4 14
April 30 51 11/16 34 22 1/2 16 5/8
July 31 40 5/8 30 3/8 30 18
October 31 31 13/16 14 41 1/8 28
</TABLE>
At December 31, 1998 there were 2,150 shareholders of record compared with 2,613
on December 31, 1997. No dividends were paid on the Company's common stock in
1998 or 1997, and the Company does not currently anticipate paying cash
dividends in the future.
INVESTOR RELATIONS CONTACT:
B. NORRIS BATTIN
10 Faraday, Irvine, CA 92618-1850
Voice: (949) 597-4700, Fax: (949) 597-0662
email: [email protected]
INVESTOR INFORMATION:
Corporate information, including the current share price, recent news releases
and the Company's annual report on Securities and Exchange Commission Form 10-K
without exhibits, is available free of charge through the Company's interactive
stockholder communication system. Call 1-800-334-1986, seven days a week, 24
hours a day. Visit The Cooper Companies, Inc. on the Worldwide Web at
www.coopercos.com.
ANNUAL MEETING
The annual meeting of stockholders of The Cooper Companies, Inc. will be held on
March 18, 1999 at the Marriott East Side Hotel, New York, NY at 10:00 A.M.
TRANSFER AGENT
American Stock Transfer & Trust Company
40 Wall Street, New York, NY 10005
CERTIFIED PUBLIC ACCOUNTANTS
KPMG LLP
STOCK EXCHANGE LISTINGS
The New York Stock Exchange
The Pacific Exchange
Ticker Symbol "COO"
TRADEMARKS
The following trademarks italicized in this report are owned by, licensed to or
distributed by The Cooper Companies, Inc., its subsidiaries or affiliates:
Alliance Toric, Cerveillance, CooperFlex'TM', CooperSurgical Infrared
Coagulator, Cooper Toric, Encore, FemExam TestCard System'TM', FemExam pH and
Amines Test Card, Frequency 55, Hydrasoft, Hyskon, Natural Touch'TM',
Preference, Rumi and Unimar.
54
<PAGE>
<PAGE>
[LOGO]
THE COOPER COMPANIES, INC.
10 Faraday, Irvine, California 92618-1850
Voice: (949) 597-1700, Fax (949) 597-0662, www.coopercos.com
[LOGO]
<PAGE>
<PAGE>
THE COOPER COMPANIES, INC.
NARROWING OUR FOCUS -- EXPANDING OUR REACH -- 1998 ANNUAL REPORT
<PAGE>
<PAGE>
Exhibit 21
SUBSIDIARIES OF
THE COOPER COMPANIES, INC.
A DELAWARE CORPORATION
<TABLE>
<CAPTION>
JURISDICTION OF
NAME INCORPORATION
- -------------------------------------------------------------------------------------------
<S> <C>
The Cooper Healthcare Group, Inc. Delaware
Unimar, Inc. California
CooperVision Pharmaceuticals, Inc. Delaware
The Cooper Real Estate Group, Inc. Delaware
CooperSurgical Acquisition Corp. Delaware
CooperVision, Inc. New York
CooperVision, Inc. Canada
Marlow Surgical Acquisition (dormant) Delaware
CooperVision GB Finance, Inc. (dormant) Delaware
CooperVision GB Services, Inc. (dormant) Delaware
Hospital Group of America, Inc. Delaware
HGA Management Services, Inc. Delaware
Hospital Group of Delaware, Inc. Delaware
Hospital Group of Illinois, Inc. Illinois
Hospital Group of Louisiana, Inc. Louisiana
Residential Centers of Indiana, Inc. Delaware
Hospital Group of New Jersey, Inc. New Jersey
Hampton Learning Center, Inc. New Jersey
HGNJ, Inc. New Jersey
Arlington Center for Recovery, L.L.C. Illinois
MeadowWood Health Services, L.L.C. Delaware
CooperSurgical, Inc. Delaware
CooperSurgical, Inc. Canada
HBH Medizintechnik GmbH Germany
Aspect Vision Holdings, Limited England-Wales
Aspect Vision Care Limited England-Wales
Contact Lens Technologies Limited England-Wales
Aspect Specialty Limited England-Wales
New Focus HealthCare Limited England-Wales
Aspect Vision Italia s.r.l. Italy
Focus Solutions Limited England-Wales
Averlan Company Limited England-Wales
Aspect Contact Lenses Limited England-Wales
</TABLE>
NOTE: Except for CooperSurgical and its 52% owned subsidiary, HBH Medizintechnik
GmbH, and Aspect Vision Italia s.r.l., each subsidiary is wholly-owned either by
The Cooper Companies, Inc. or by the wholly-owned subsidiary under which it is
indented in the list above. In the case of CooperSurgical, Inc., 99.8% of the
company is owned by The Cooper Companies, Inc. and the remaining .2% is owned by
members of CooperSurgical's Medical Advisory Board. In the case of Aspect Vision
Italia s.r.l., 75.713% is owned by The Cooper Companies, Inc. and 24.287% is
owned by Giacomo Grassi.
